Dabrafenib – Uses, Dosage, Side Effects, Interaction

RxHarun

1 year ago

Dabrafenib is a selective inhibitor of mutated forms of BRAF kinase and is used alone or in combination with trametinib in the treatment of advanced malignant melanoma. Dabrafenib therapy is associated with transient elevations in serum aminotransferase during therapy but has not been linked to instances of clinically apparent acute liver injury.

Dabrafenib is an orally bioavailable inhibitor of the B-RAF (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-RAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene. B-RAF belongs to the RAF/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.

Dabrafenib is an organofluorine compound and antineoplastic agent, used as its mesylate salt in the treatment of metastatic melanoma. It has a role as an antineoplastic agent, a B-Raf inhibitor, and an anticoronaviral agent. It is a sulfonamide, an organofluorine compound, a member of 1,3-thiazoles, and an aminopyrimidine. Dabrafenib mesylate is a methanesulfonate (mesylate) salt prepared from equimolar amounts of dabrafenib and methanesulfonic acid. Used for treatment of metastatic melanoma. It has a role as an antineoplastic agent and a B-Raf inhibitor. It contains a dabrafenib.

Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-RAF (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-RAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene. B-RAF belongs to the RAF/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.

Mechanism of Action

Dabrafenib is an orally bioavailable inhibitor of B-RAF (BRAF) protein with antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-RAF, which may inhibit the proliferation of tumor cells that contain a mutated BRAF gene. B-RAF belongs to the RAF/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/Extracellular Signal-regulated Kinases signaling pathway, which may be constitutively activated due to BRAF gene mutations.

Dabrafenib causes inhibition of phosphorylated extracellular signal-regulated kinase (ERK). This indicates a decrease in cell proliferation. Furthermore, within 24 hours of administration, downstream mediators of the MAPK pathway were inhibited. The melanoma approval for use with Mekinist is based on results from COMBI-AD, a Phase III study of 870 patients with Stage III BRAF V600E/K mutation-positive melanoma treated with Tafinlar + Mekinist after complete surgical resection. Patients received doses of Tafinlar (150 mg BID) + Mekinist (2 mg QD) combination (n = 438) or matching placebos (n = 432). After a median follow-up of 2.8 years, the primary endpoint of relapse-free survival (RFS) was met. Thus, Tafinlar in combination with Mekinist treats melanoma. In the case of thyroid cancer, Dabrafenib plus Trametinib is the first regimen demonstrated to have potent clinical activity in BRAF V600E–mutated anaplastic thyroid cancer and is well tolerated. These findings represent a meaningful therapeutic advance for this orphan disease.

Indications

Tafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Tafinlar in combination with [DB08911] is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of a durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for Tafinlar in combination with trametinib. In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Melanoma – Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Adjuvant treatment of melanoma – Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
Non-small cell lung cancer (NSCLC) – Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
Non-small cell lung cancer (NSCLC) – Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation
Treatment of melanoma, Treatment of solid malignant tumors (excluding melanoma)
Dabrafenib was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.^[rx] Later, it was used in combination with trametinib for the treatment of unresectable or metastatic melanoma with V600E or V600K mutations, either as primary treatment or adjuvant treatment.^[rx]
Metastatic Anaplastic Thyroid Cancer
Metastatic Melanoma
Metastatic Non-Small Cell Lung Cancer
Unresectable Melanoma
Unresectable or Metastatic Solid Tumors
Locally advanced Thyroid Cancer, Anaplastic

Use in Cancer

Dabrafenib mesylate is approved to be used alone or with trametinib to treat patients whose cancer has a certain mutation in the BRAF gene, including:

Anaplastic thyroid cancer is locally advanced or has spread to other parts of the body and cannot be treated with local therapy. It is used with trametinib.
Melanoma. It is used:
- Trametinib in patients who have had surgery to remove cancer that has spread to the lymph nodes.
- Alone or with trametinib in patients whose cancer cannot be removed by surgery or has spread to other parts of the body.
Non-small cell lung cancer that has metastasized. It is used with trametinib.
Solid tumors. It is used with trametinib in adults and children aged 6 years and older whose tumors cannot be removed by surgery or have spread to other parts of the body and have gotten worse after other treatments and cannot be treated with other therapies.¹

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that dabrafenib mesylate provides a clinical benefit in these patients.

Dabrafenib mesylate is also being studied in the treatment of other types of cancer.

Contraindications

Dabrafenib is not indicated for the treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC
squamous cell carcinoma
diabetes
inflammation of the iris – the colored part of the eyeball
inflammation of the uvea of the eye
chronic heart failure
abnormal EKG with QT changes from birth
bleeding
a body temperature higher than 101 degrees Fahrenheit
pregnancy
a patient who is producing milk and breastfeeding
basal cell carcinoma of the skin
anemia from pyruvate kinase and G6PD deficiencies
a type of slow growing skin cancer called a keratoacanthoma
progression of cancer with the RAS mutation
Child-Pugh class B liver impairment
Child-Pugh class C liver impairment

Dosage

Strengths: 75 mg; 50 mg

Non-Small Cell Lung Cancer

150 mg orally 2 times a day, either as monotherapy or in combination with trametinib
Duration of Therapy: Until disease progression or unacceptable toxicity occurs
Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to treatment initiation with FDA-approved test.
Take doses approximately 12 hours apart.
Take this drug at least 1 hour before or 2 hours after a meal.
Do not take a missed dose within 6 hours of the next dose.
Do not open, crush, or break capsules.
As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an approved test
In combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an approved test
In combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an approved test, and involvement of lymph node(s), following complete resection
In combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an approved test
In combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options

Melanoma – Metastatic

150 mg orally 2 times a day, either as monotherapy or in combination with trametinib
Duration of Therapy: Until disease progression or unacceptable toxicity occurs
Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to treatment initiation with FDA-approved test.
Take doses approximately 12 hours apart.
Take this drug at least 1 hour before or 2 hours after a meal.
Do not take a missed dose within 6 hours of the next dose.
Do not open, crush, or break capsules.
As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an approved test
In combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an approved test
In combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an approved test, and involvement of lymph node(s), following complete resection
In combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an approved test
In combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options

Thyroid Cancer

150 mg orally 2 times a day, either as monotherapy or in combination with trametinib
Duration of Therapy: Until disease progression or unacceptable toxicity occurs
Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to treatment initiation with FDA-approved test.
Take doses approximately 12 hours apart.
Take this drug at least 1 hour before or 2 hours after a meal.
Do not take a missed dose within 6 hours of the next dose.
Do not open, crush, or break capsules.
As a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an approved test
In combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an approved test
In combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an approved test, and involvement of lymph node(s), following complete resection
In combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an approved test
In combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options

For Oral

For oral dosage form (capsules):

For melanoma (skin cancer), non-small cell lung cancer, anaplastic thyroid cancer, and solid tumors:

Adults—150 milligrams (mg) 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated.
Children 6 years of age and older—The dose is based on body weight and must be determined by your doctor.
Weighing 51 kilograms (kg) or more—150 milligrams (mg) 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated.
Weighing 38 to 50 kg—100 mg 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated.
Weighing 26 to 37 kg—75 mg 2 times a day, taken 12 hours apart. Your doctor may adjust your dose as needed and tolerated.
Children younger than 6 years of age—Use and dose must be determined by your doctor.

Dose Adjustments

DOSE REDUCTIONS FOR ADVERSE REACTIONS:

First Dose Reduction: 100 mg twice a day
Second Dose Reduction: 75 mg twice a day
Third Dose Reduction: 50 mg twice a day
Subsequent Modification: Permanently discontinue treatment if unable to tolerate 50 mg twice a day.

For New Primary Cutaneous Malignancies that develop: No dose modifications are recommended.
For New Primary Non-Cutaneous Malignancies: Permanently discontinue in patients who develop RAS mutation-positive non-cutaneous malignancies.

Fever 101.3F to 104F:

Withhold dabrafenib until the adverse reaction resolves, then resume at the same dose or at a reduced level.
NEW PRIMARY CUTANEOUS MALIGNANCIES: No adjustment is recommended.
NEW PRIMARY NON-CUTANEOUS MALIGNANCIES: Permanently discontinue treatment in patients who develop RAS mutation-positive non-cutaneous malignancies.

CARDIAC:

Symptomatic Congestive Heart Failure; Absolute Decrease in Left Ventricular Ejection Fraction [LVEF] of Greater Than 20% from Baseline that is Below Lower Level of Normal [LLN]): Withhold treatment, then resume at the same dose upon recovery of cardiac function.

PYREXIA:

Fever of 101.3 to 104 Degrees Fahrenheit: Withhold treatment until fever resolves, then resume at the same or lower dose level.
Fever Higher Than 104 Degrees Fahrenheit; Fever Complicated by Rigors, Hypotension, Dehydration, or Renal Failure: Withhold treatment until fever resolves, then resume at a lower dose level OR permanently discontinue treatment.

SKIN TOXICITY (Intolerable Grade 2, Grade 3, or Grade 4): Withhold treatment for up to 3 weeks

If Improved: Resume at a lower dose.
If Not Improved: Permanently discontinue treatment.

UVEITIS (Severe OR Mild/Moderate that Does Not Respond to Ocular Therapy): Withhold treatment for up to 6 weeks.

If Improved to Grade 0 to 1: Resume at same or lower dose level.
If Not Improved: Permanently discontinue treatment.

OTHER ADVERSE REACTIONS:
INTOLERABLE GRADE 2; ANY GRADE 3: Withhold treatment.

If Improved to Grade 0 to 1: Resume at a lower dose level.
If Not Improved: Permanently discontinue treatment.

FIRST OCCURRENCE OF ANY GRADE 4: Withhold treatment until improvement to Grade 0 to 1, then resume at a lower dose level OR permanently discontinue treatment.
RECURRENT GRADE 4: Permanently discontinue treatment.
Comments:

Dose adjustments are NOT recommended for this drug when it is administered in combination with trametinib for the following adverse reactions: retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED), interstitial lung disease (ILD)/pneumonitis, and uncomplicated venous thromboembolism.
Consult the manufacturer’s product information for trametinib dosing recommendations.

Administration Advice:

Direct patients to take this drug at least 1 hour before or 2 hours after a meal, and at similar times every day with an interval of approximately 12 hours between doses.
Instruct patients to swallow drug capsules whole with water, and not to open, crush, chew, or break capsules.
Warn patients not to mix capsule contents with food or liquids due to the chemical instability of this drug.
Advise patients not to take a missed dose within 6 hours of the next scheduled dose.
In the event of a vomited dose, counsel patients not to retake that dose and to resume dosing with the next scheduled dose.
Consult the manufacturer product information for trametinib dosing recommendations prior to initiation of combination treatment with this drug.

Side Effects

The Most Common

headache
joint, muscle, or back pain
nausea
diarrhea
constipation
loss of appetite
cough, runny nose, or sore throat
hair loss
tiredness
changes in skin (new wart, skin sore, or red bump that bleeds or does not heal)
change in size or color of a mole
rash, red skin, or pimples
fever
fainting
dizziness, lightheadedness, or weakness
chills
decreased urination
swelling of hands, feet, ankles, or lower legs
frequent urination
increased thirst
eye pain
red or swollen eyelids
sensitivity to light
blurred vision or vision changes, including seeing halos (blurred outline around objects) or colored dots
swelling, pain, redness, or peeling of skin on the palms and soles of the feet
ongoing pain that begins in the stomach area but may spread to the back
unusual bleeding or bruising
bloody or black, tarry stools
coughing up or vomiting blood or material that looks like coffee grounds
chest pain
shortness of breath
swelling of the hands, feet, ankles or lower legs
fast, irregular, or pounding heartbeat
yellowing of the skin and eyes

More common

Bleeding gums
bloody, black, or tarry stools
bloody or cloudy urine
blurred vision
coughing up blood
difficulty in breathing or swallowing
dizziness
dry mouth
fever
flushed, dry skin
fruit-like breath odor
greatly decreased frequency of urination or amount of urine
headache
heartburn
increased hunger
increased thirst
increased urination
indigestion
lump or growth on the skin
nausea
nosebleed
prolonged bleeding from cuts
red or black, tarry stools
red or dark brown urine
redness, swelling, or pain of the skin
scaling of the skin on the hands and feet
skin blisters
skin rash
stomach pain or cramps
sweating
swelling of the feet or lower legs
tingling of the hands and feet
ulceration of the skin
unable to move
unexplained weight loss
unusual tiredness or weakness
vomiting
vomiting of material that looks like coffee grounds, severe and continuing

Rare

Blurred vision or other change in vision
change in color vision
difficulty seeing at night
eye pain
increased sensitivity of the eyes to sunlight
redness of the eye
tearing
Blistering, peeling, loosening of the skin
chills
cough
diarrhea
itching
joint or muscle pain
red skin lesions, often with a purple center
sore throat
sores, ulcers, or white spots in the mouth or on lips
swollen, painful, or tender lymph glands in the neck, armpit, or groin
yellow eyes or skin

Drug Interaction

DRUG	INTERACTION
Benzodiazepine	The serum concentration of 1,2-Benzodiazepine can be decreased when it is combined with Dabrafenib.
Abacavir	The metabolism of Abacavir can be decreased when combined with Dabrafenib.
Abametapir	The serum concentration of Dabrafenib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Dabrafenib can be increased when combined with Abatacept.
Abemaciclib	The serum concentration of Abemaciclib can be decreased when it is combined with Dabrafenib.
Abiraterone	The serum concentration of Abiraterone can be decreased when it is combined with Dabrafenib.
Abrocitinib	The metabolism of Abrocitinib can be increased when combined with Dabrafenib.
Acalabrutinib	The serum concentration of Acalabrutinib can be decreased when it is combined with Dabrafenib.
Acamprosate	The excretion of Acamprosate can be decreased when combined with Dabrafenib.
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Dabrafenib.
Acenocoumarol	The serum concentration of Acenocoumarol can be decreased when it is combined with Dabrafenib.
Acetaminophen	The serum concentration of Acetaminophen can be decreased when it is combined with Dabrafenib.
Acetazolamide	The metabolism of Dabrafenib can be decreased when combined with Acetazolamide.
Acetohexamide	The serum concentration of Acetohexamide can be decreased when it is combined with Dabrafenib.
Acetyl sulfisoxazole	The metabolism of Dabrafenib can be decreased when combined with Acetyl sulfisoxazole.
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Dabrafenib.
Acrivastine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Acrivastine.
Acyclovir	The excretion of Acyclovir can be decreased when combined with Dabrafenib.
Adalimumab	The metabolism of Dabrafenib can be increased when combined with Adalimumab.
Adefovir dipivoxil	The excretion of Adefovir dipivoxil can be decreased when combined with Dabrafenib.
Adenosine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Adenosine.
Afatinib	The serum concentration of Dabrafenib can be increased when it is combined with Afatinib.
Agomelatine	The metabolism of Dabrafenib can be decreased when combined with Agomelatine.
Ajmaline	The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Dabrafenib.
Albendazole	The serum concentration of Albendazole can be decreased when it is combined with Dabrafenib.
Albiglutide	The therapeutic efficacy of Albiglutide can be decreased when used in combination with Dabrafenib.
Alclometasone	The serum concentration of Alclometasone can be decreased when it is combined with Dabrafenib.
Aldesleukin	The metabolism of Dabrafenib can be decreased when combined with Aldesleukin.
Alectinib	The metabolism of Alectinib can be increased when combined with Dabrafenib.
Alfentanil	The serum concentration of Alfentanil can be decreased when it is combined with Dabrafenib.
Alfuzosin	The metabolism of Alfuzosin can be decreased when combined with Dabrafenib.
Alimemazine	The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Dabrafenib.
Aliskiren	The serum concentration of Aliskiren can be decreased when it is combined with Dabrafenib.
Allopurinol	The excretion of Allopurinol can be decreased when combined with Dabrafenib.
Almasilate	Almasilate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Almotriptan	The serum concentration of Almotriptan can be decreased when it is combined with Dabrafenib.
Alogliptin	The serum concentration of Alogliptin can be decreased when it is combined with Dabrafenib.
Alosetron	The serum concentration of Alosetron can be decreased when it is combined with Dabrafenib.
Alpelisib	The serum concentration of Alpelisib can be increased when it is combined with Dabrafenib.
Alprazolam	The metabolism of Alprazolam can be decreased when combined with Dabrafenib.
Alprostadil	The excretion of Alprostadil can be decreased when combined with Dabrafenib.
Aluminium phosphate	Aluminium phosphate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxide	Aluminum hydroxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Amantadine	The serum concentration of Amantadine can be increased when it is combined with Dabrafenib.
Ambrisentan	The serum concentration of Ambrisentan can be decreased when it is combined with Dabrafenib.
Ambroxol	The serum concentration of Ambroxol can be decreased when it is combined with Dabrafenib.
Amcinonide	The serum concentration of Amcinonide can be decreased when it is combined with Dabrafenib.
Amifampridine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Amifampridine.
Aminoglutethimide	The metabolism of Dabrafenib can be increased when combined with Aminoglutethimide.
Aminohippuric acid	The excretion of Aminohippuric acid can be decreased when combined with Dabrafenib.
Aminophenazone	The serum concentration of Aminophenazone can be decreased when it is combined with Dabrafenib.
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Dabrafenib.
Amiodarone	The serum concentration of Dabrafenib can be increased when it is combined with Amiodarone.
Amisulpride	The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Dabrafenib.
Amitriptyline	The serum concentration of Amitriptyline can be decreased when it is combined with Dabrafenib.
Amlodipine	The metabolism of Amlodipine can be increased when combined with Dabrafenib.
Amobarbital	The metabolism of Dabrafenib can be increased when combined with Amobarbital.
Amodiaquine	The serum concentration of Amodiaquine can be decreased when it is combined with Dabrafenib.
Amoxapine	The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Dabrafenib.
Amprenavir	The serum concentration of Dabrafenib can be increased when it is combined with Amprenavir.
Anagrelide	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Anagrelide.
Anakinra	The metabolism of Dabrafenib can be increased when combined with Anakinra.
Anastrozole	The serum concentration of Anastrozole can be decreased when it is combined with Dabrafenib.
Antazoline	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Antazoline.
Antipyrine	The serum concentration of Antipyrine can be decreased when it is combined with Dabrafenib.
Apalutamide	The serum concentration of Apalutamide can be increased when it is combined with Dabrafenib.
Apixaban	The serum concentration of Apixaban can be decreased when it is combined with Dabrafenib.
Apomorphine	The serum concentration of Apomorphine can be decreased when it is combined with Dabrafenib.
Apremilast	The serum concentration of Apremilast can be decreased when it is combined with Dabrafenib.
Aprepitant	The serum concentration of Aprepitant can be decreased when it is combined with Dabrafenib.
Arformoterol	The serum concentration of Arformoterol can be decreased when it is combined with Dabrafenib.
Aripiprazole	The serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib.
Aripiprazole	The serum concentration of Aripiprazole lauroxil can be decreased when it is combined with Dabrafenib.
Armodafinil	The metabolism of Dabrafenib can be increased when combined with Armodafinil.
Arsenic trioxide	The serum concentration of Dabrafenib can be increased when it is combined with Arsenic trioxide.
Artemether	The serum concentration of Artemether can be decreased when it is combined with Dabrafenib.
Articaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Articaine.
Asciminib	The serum concentration of Dabrafenib can be increased when it is combined with Asciminib.
Asenapine	The serum concentration of Asenapine can be decreased when it is combined with Dabrafenib.
Astemizole	The serum concentration of Astemizole can be decreased when it is combined with Dabrafenib.
Asunaprevir	The serum concentration of Asunaprevir can be decreased when it is combined with Dabrafenib.
Atazanavir	The serum concentration of Dabrafenib can be increased when it is combined with Atazanavir.
Atogepant	The serum concentration of Atogepant can be increased when it is combined with Dabrafenib.
Atomoxetine	The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dabrafenib.
Atorvastatin	The metabolism of Atorvastatin can be decreased when combined with Dabrafenib.
Atovaquone	The serum concentration of Atovaquone can be decreased when it is combined with Dabrafenib.
Atropine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Atropine.
Avacopan	The serum concentration of Avacopan can be decreased when it is combined with Dabrafenib.
Avanafil	The serum concentration of Avanafil can be decreased when it is combined with Dabrafenib.
Avapritinib	The serum concentration of Avapritinib can be decreased when it is combined with Dabrafenib.
Avatrombopag	The metabolism of Dabrafenib can be increased when combined with Avatrombopag.
Avibactam	The excretion of Avibactam can be decreased when combined with Dabrafenib.
Axitinib	The serum concentration of Axitinib can be decreased when it is combined with Dabrafenib.
Azatadine	The risk or severity of QTc prolongation can be increased when Azatadine is combined with Dabrafenib.
Azelastine	The serum concentration of Azelastine can be decreased when it is combined with Dabrafenib.
Azithromycin	The serum concentration of Azithromycin can be decreased when it is combined with Dabrafenib.
Baricitinib	The serum concentration of Baricitinib can be increased when it is combined with Dabrafenib.
Bazedoxifene	The metabolism of Bazedoxifene can be decreased when combined with Dabrafenib.
Beclomethasone dipropionate	The serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Dabrafenib.
Bedaquiline	The serum concentration of Bedaquiline can be decreased when it is combined with Dabrafenib.

Belantamab	The serum concentration of Dabrafenib can be increased when it is combined with Belantamab mafodotin.
Belinostat	The metabolism of Belinostat can be decreased when combined with Dabrafenib.
Belumosudil	The serum concentration of Belumosudil can be decreased when it is combined with Dabrafenib.
Belzutifan	The serum concentration of Dabrafenib can be decreased when it is combined with Belzutifan.
Bempedoic acid	The excretion of Bempedoic acid can be decreased when combined with Dabrafenib.
Bendamustine	The serum concentration of Bendamustine can be increased when it is combined with Dabrafenib.
Benzatropine	The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Dabrafenib.
Benzocaine	The serum concentration of Benzocaine can be decreased when it is combined with Dabrafenib.
Benzphetamine	The serum concentration of Benzphetamine can be decreased when it is combined with Dabrafenib.
Benzyl alcohol	The serum concentration of Benzyl alcohol can be decreased when it is combined with Dabrafenib.
Benzylpenicillin	The excretion of Benzylpenicillin can be decreased when combined with Dabrafenib.
Bepridil	The serum concentration of Bepridil can be decreased when it is combined with Dabrafenib.
Berotralstat	The serum concentration of Berotralstat can be increased when it is combined with Dabrafenib.
Betamethasone	The serum concentration of Betamethasone can be decreased when it is combined with Dabrafenib.
Betamethasone phosphate	The serum concentration of Betamethasone phosphate can be decreased when it is combined with Dabrafenib.
Betrixaban	The serum concentration of Dabrafenib can be increased when it is combined with Betrixaban.
Bexarotene	The serum concentration of Bexarotene can be decreased when it is combined with Dabrafenib.
Bezafibrate	The serum concentration of Bezafibrate can be decreased when it is combined with Dabrafenib.
Bicalutamide	The serum concentration of Bicalutamide can be decreased when it is combined with Dabrafenib.
Bictegravir	The serum concentration of Bictegravir can be decreased when it is combined with Dabrafenib.
Bifonazole	The metabolism of Dabrafenib can be decreased when combined with Bifonazole.
Bilastine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Bilastine.
Bimekizumab	The metabolism of Dabrafenib can be increased when combined with Bimekizumab.
Binimetinib	The metabolism of Binimetinib can be decreased when combined with Dabrafenib.
Bioallethrin	The serum concentration of Bioallethrin can be decreased when it is combined with Dabrafenib.
Bismuth subnitrate	Bismuth subnitrate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bisoprolol	The serum concentration of Bisoprolol can be decreased when it is combined with Dabrafenib.
Boceprevir	The serum concentration of Dabrafenib can be increased when it is combined with Boceprevir.
Bortezomib	The serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib.
Bosentan	The serum concentration of Bosentan can be decreased when it is combined with Dabrafenib.
Bosutinib	The serum concentration of Bosutinib can be decreased when it is combined with Dabrafenib.
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib.
Bretylium	The risk or severity of QTc prolongation can be increased when Bretylium is combined with Dabrafenib.
Brexpiprazole	The serum concentration of Brexpiprazole can be decreased when it is combined with Dabrafenib.
Brigatinib	The serum concentration of Brigatinib can be decreased when it is combined with Dabrafenib.
Brincidofovir	The serum concentration of Brincidofovir can be increased when it is combined with Dabrafenib.
Brinzolamide	The serum concentration of Brinzolamide can be decreased when it is combined with Dabrafenib.
Brivaracetam	The serum concentration of Brivaracetam can be decreased when it is combined with Dabrafenib.
Bromocriptine	The serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib.
Brompheniramine	The serum concentration of Brompheniramine can be decreased when it is combined with Dabrafenib.
Buclizine	The risk or severity of QTc prolongation can be increased when Buclizine is combined with Dabrafenib.
Budesonide	The serum concentration of Budesonide can be decreased when it is combined with Dabrafenib.
Bumetanide	The excretion of Bumetanide can be decreased when combined with Dabrafenib.
Bupivacaine	The serum concentration of Bupivacaine can be decreased when it is combined with Dabrafenib.
Buprenorphine	The serum concentration of Buprenorphine can be decreased when it is combined with Dabrafenib.
Bupropion	The serum concentration of Bupropion can be decreased when it is combined with Dabrafenib.
Buserelin	The risk or severity of QTc prolongation can be increased when Buserelin is combined with Dabrafenib.
Buspirone	The serum concentration of Buspirone can be decreased when it is combined with Dabrafenib.
Busulfan	The serum concentration of Busulfan can be decreased when it is combined with Dabrafenib.
Butacaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Butacaine.
Butalbital	The metabolism of Dabrafenib can be increased when combined with Butalbital.
Butamben	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Butamben.
Butriptyline	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Butriptyline.
Cabazitaxel	The serum concentration of Cabazitaxel can be decreased when it is combined with Dabrafenib.
Cabergoline	The serum concentration of Cabergoline can be decreased when it is combined with Dabrafenib.
Cabotegravir	The metabolism of Cabotegravir can be decreased when combined with Dabrafenib.
Cabozantinib	The serum concentration of Cabozantinib can be decreased when it is combined with Dabrafenib.
Caffeine	Caffeine may decrease the excretion rate of Dabrafenib which could result in a higher serum level.
Calcitriol	The serum concentration of Calcitriol can be decreased when it is combined with Dabrafenib.
Calcium carbonate	Calcium carbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Canagliflozin	The serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib.
Canakinumab	The metabolism of Dabrafenib can be increased when combined with Canakinumab.
Candesartan cilexetil	The serum concentration of Dabrafenib can be increased when it is combined with Candesartan cilexetil.
Candicidin	The metabolism of Dabrafenib can be decreased when combined with Candicidin.
Cannabidiol	The serum concentration of Cannabidiol can be decreased when it is combined with Dabrafenib.
Capecitabine	The metabolism of Capecitabine can be decreased when combined with Dabrafenib.
Capmatinib	The serum concentration of Capmatinib can be decreased when it is combined with Dabrafenib.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Capsaicin.
Captopril	The excretion of Captopril can be decreased when combined with Dabrafenib.
Carbamazepine	The serum concentration of Carbamazepine can be decreased when it is combined with Dabrafenib.
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Carbinoxamine.
Carfilzomib	The serum concentration of Dabrafenib can be increased when it is combined with Carfilzomib.
Cariprazine	The serum concentration of Cariprazine can be decreased when it is combined with Dabrafenib.
Carisoprodol	The serum concentration of Carisoprodol can be decreased when it is combined with Dabrafenib.
Carvedilol	The serum concentration of Carvedilol can be decreased when it is combined with Dabrafenib.
Caspofungin	The excretion of Caspofungin can be decreased when combined with Dabrafenib.
Cefaclor	The excretion of Cefaclor can be decreased when combined with Dabrafenib.
Cefazolin	The excretion of Cefazolin can be decreased when combined with Dabrafenib.
Cefdinir	The excretion of Cefdinir can be decreased when combined with Dabrafenib.
Cefotiam	The excretion of Cefotiam can be decreased when combined with Dabrafenib.
Cefradine	The metabolism of Dabrafenib can be increased when combined with Cefradine.
Ceftibuten	The excretion of Ceftibuten can be decreased when combined with Dabrafenib.
Ceftizoxime	The excretion of Ceftizoxime can be decreased when combined with Dabrafenib.
Celecoxib	The serum concentration of Celecoxib can be decreased when it is combined with Dabrafenib.
Celiprolol	The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Dabrafenib.
Cenobamate	The serum concentration of Cenobamate can be decreased when it is combined with Dabrafenib.
Cephalexin	The serum concentration of Cephalexin can be decreased when it is combined with Dabrafenib.
Ceritinib	The serum concentration of Ceritinib can be decreased when it is combined with Dabrafenib.
Cerivastatin	The serum concentration of Cerivastatin can be decreased when it is combined with Dabrafenib.
Certolizumab pegol	The metabolism of Dabrafenib can be increased when combined with Certolizumab pegol.
Cetirizine	The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Dabrafenib.
Cevimeline	The serum concentration of Cevimeline can be decreased when it is combined with Dabrafenib.
Chenodeoxycholic acid	The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Dabrafenib.
Chloramphenicol	The metabolism of Dabrafenib can be decreased when combined with Chloramphenicol.
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Chlorcyclizine.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Chloroprocaine.
Chloroquine	The serum concentration of Chloroquine can be decreased when it is combined with Dabrafenib.
Chlorpheniramine	The serum concentration of Chlorpheniramine can be decreased when it is combined with Dabrafenib.
Chlorpromazine	The serum concentration of Chlorpromazine can be decreased when it is combined with Dabrafenib.
Chlorpropamide	The serum concentration of Chlorpropamide can be decreased when it is combined with Dabrafenib.

Chlorprothixene	The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Dabrafenib.
Chlorzoxazone	The serum concentration of Chlorzoxazone can be decreased when it is combined with Dabrafenib.
Cholecalciferol	The serum concentration of Cholecalciferol can be decreased when it is combined with Dabrafenib.
Cholecystokinin	The excretion of Cholecystokinin can be decreased when combined with Dabrafenib.
Cholesterol	Cholesterol may increase the excretion rate of Dabrafenib which could result in a lower serum level and potentially a reduction in efficacy.
Cholic Acid	The excretion of Cholic Acid can be decreased when combined with Dabrafenib.
Choline	The serum concentration of Choline can be increased when it is combined with Dabrafenib.
Choline salicylate	The serum concentration of Choline salicylate can be increased when it is combined with Dabrafenib.
Ciclesonide	The serum concentration of Ciclesonide can be decreased when it is combined with Dabrafenib.
Cidofovir	The excretion of Cidofovir can be decreased when combined with Dabrafenib.
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Dabrafenib.
Cimetidine	Cimetidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cinacalcet	The serum concentration of Cinacalcet can be decreased when it is combined with Dabrafenib.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Cinchocaine.
Cinnarizine	The serum concentration of Cinnarizine can be decreased when it is combined with Dabrafenib.
Cinoxacin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Cinoxacin.
Ciprofloxacin	The metabolism of Dabrafenib can be decreased when combined with Ciprofloxacin.
Cisapride	The serum concentration of Cisapride can be decreased when it is combined with Dabrafenib.
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Dabrafenib.
Citalopram	The serum concentration of Citalopram can be decreased when it is combined with Dabrafenib.
Cladribine	Dabrafenib may decrease the excretion rate of Cladribine which could result in a higher serum level.
Clarithromycin	The serum concentration of Dabrafenib can be increased when it is combined with Clarithromycin.
Clemastine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Clemastine.
Clevidipine	The serum concentration of Clevidipine can be decreased when it is combined with Dabrafenib.
Clindamycin	The metabolism of Clindamycin can be increased when combined with Dabrafenib.
Clobazam	The serum concentration of Clobazam can be decreased when it is combined with Dabrafenib.
Clobetasol	The serum concentration of Clobetasol can be decreased when it is combined with Dabrafenib.
Clobetasol propionate	The serum concentration of Clobetasol propionate can be decreased when it is combined with Dabrafenib.
Clobetasone	The serum concentration of Clobetasone can be decreased when it is combined with Dabrafenib.
Clofarabine	The serum concentration of Clofarabine can be increased when it is combined with Dabrafenib.
Clofazimine	The serum concentration of Dabrafenib can be increased when it is combined with Clofazimine.
Clofibrate	The serum concentration of Clofibrate can be decreased when it is combined with Dabrafenib.
Clomifene	The serum concentration of Dabrafenib can be increased when it is combined with Clomifene.
Clomipramine	The serum concentration of Clomipramine can be decreased when it is combined with Dabrafenib.
Clonazepam	The metabolism of Clonazepam can be increased when combined with Dabrafenib.
Clonidine	The serum concentration of Clonidine can be decreased when it is combined with Dabrafenib.
Clopidogrel	The serum concentration of Clopidogrel can be decreased when it is combined with Dabrafenib.
Clorazepic acid	The serum concentration of Clorazepic acid can be decreased when it is combined with Dabrafenib.
Clotiazepam	The serum concentration of Clotiazepam can be decreased when it is combined with Dabrafenib.
Clozapine	The serum concentration of Clozapine can be decreased when it is combined with Dabrafenib.
Cobicistat	The serum concentration of Dabrafenib can be increased when it is combined with Cobicistat.
Cobimetinib	The serum concentration of Cobimetinib can be decreased when it is combined with Dabrafenib.
Cocaine	The serum concentration of Cocaine can be decreased when it is combined with Dabrafenib.
Codeine	The serum concentration of Codeine can be decreased when it is combined with Dabrafenib.
Colchicine	The metabolism of Colchicine can be decreased when combined with Dabrafenib.
Conivaptan	The serum concentration of Dabrafenib can be increased when it is combined with Conivaptan.
Conjugated estrogens	The serum concentration of Conjugated estrogens can be decreased when it is combined with Dabrafenib.
Copanlisib	The serum concentration of Copanlisib can be decreased when it is combined with Dabrafenib.
Corticotropin	The serum concentration of Corticotropin can be decreased when it is combined with Dabrafenib.
Cortisone acetate	The serum concentration of Cortisone acetate can be decreased when it is combined with Dabrafenib.
Crizotinib	The metabolism of Dabrafenib can be decreased when combined with Crizotinib.
Curcumin	The serum concentration of Dabrafenib can be increased when it is combined with Curcumin.
Cyclandelate	The serum concentration of Cyclandelate can be decreased when it is combined with Dabrafenib.
Cyclizine	The metabolism of Dabrafenib can be decreased when combined with Cyclizine.
Cyclobenzaprine	The serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib.
Cyclophosphamide	The serum concentration of Cyclophosphamide can be decreased when it is combined with Dabrafenib.
Cyclosporine	The serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Dabrafenib.
Cyproterone acetate	The serum concentration of Cyproterone acetate can be decreased when it is combined with Dabrafenib.
Dabigatran etexilate	The serum concentration of Dabrafenib can be increased when it is combined with Dabigatran etexilate.
Daclatasvir	The serum concentration of Daclatasvir can be decreased when it is combined with Dabrafenib.
Dacomitinib	The serum concentration of Dacomitinib can be decreased when it is combined with Dabrafenib.
Dactinomycin	Dabrafenib may decrease the excretion rate of Dactinomycin which could result in a higher serum level.
Dalfampridine	The serum concentration of Dalfampridine can be increased when it is combined with Dabrafenib.
Dalfopristin	The metabolism of Dabrafenib can be decreased when combined with Dalfopristin.
Danazol	The serum concentration of Dabrafenib can be increased when it is combined with Danazol.
Dapagliflozin	The serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib.
Dapsone	The serum concentration of Dapsone can be decreased when it is combined with Dabrafenib.
Daptomycin	The serum concentration of Dabrafenib can be increased when it is combined with Daptomycin.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dabrafenib.
Daridorexant	The serum concentration of Daridorexant can be decreased when it is combined with Dabrafenib.
Darifenacin	The serum concentration of Darifenacin can be decreased when it is combined with Dabrafenib.
Darolutamide	The serum concentration of Dabrafenib can be increased when it is combined with Darolutamide.
Darunavir	The serum concentration of Dabrafenib can be increased when it is combined with Darunavir.
Dasabuvir	The serum concentration of Dasabuvir can be decreased when it is combined with Dabrafenib.
Dasatinib	The serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib.
Daunorubicin	The metabolism of Dabrafenib can be decreased when combined with Daunorubicin.
Deferasirox	The metabolism of Dabrafenib can be increased when combined with Deferasirox.
Deflazacort	The serum concentration of Deflazacort can be decreased when it is combined with Dabrafenib.
Degarelix	The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dabrafenib.
Delafloxacin	The metabolism of Dabrafenib can be increased when combined with Delafloxacin.
Delamanid	The serum concentration of Delamanid can be decreased when it is combined with Dabrafenib.
Delavirdine	The serum concentration of Dabrafenib can be increased when it is combined with Delavirdine.
Desflurane	The risk or severity of QTc prolongation can be increased when Desflurane is combined with Dabrafenib.
Desipramine	The metabolism of Dabrafenib can be decreased when combined with Desipramine.
Desloratadine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Desloratadine.
Desogestrel	The serum concentration of Desogestrel can be decreased when it is combined with Dabrafenib.
Desonide	The serum concentration of Desonide can be decreased when it is combined with Dabrafenib.
Desoxycorticosterone	The serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Dabrafenib.
Desvenlafaxine	The serum concentration of Desvenlafaxine can be decreased when it is combined with Dabrafenib.
Deutetrabenazine	The serum concentration of Deutetrabenazine can be decreased when it is combined with Dabrafenib.
Dexamethasone	The serum concentration of Dexamethasone can be decreased when it is combined with Dabrafenib.
Dexamethasone	The serum concentration of Dexamethasone acetate can be decreased when it is combined with Dabrafenib.
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dabrafenib.
Dexchlorpheniramine	The serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Dabrafenib.
Dexibuprofen	The serum concentration of Dexibuprofen can be decreased when it is combined with Dabrafenib.
Dexlansoprazole	The serum concentration of Dexlansoprazole can be decreased when it is combined with Dabrafenib.
Dextromethorphan	The serum concentration of Dextromethorphan can be decreased when it is combined with Dabrafenib.
Dextropropoxyphene	The serum concentration of Dextropropoxyphene can be decreased when it is combined with Dabrafenib.
Diacerein	The metabolism of Dabrafenib can be decreased when combined with Diacerein.

Diazepam	The serum concentration of Diazepam can be decreased when it is combined with Dabrafenib.
Diclofenac	The serum concentration of Diclofenac can be decreased when it is combined with Dabrafenib.
Dicloxacillin	The metabolism of Dabrafenib can be increased when combined with Dicloxacillin.
Dicoumarol	The serum concentration of Dicoumarol can be decreased when it is combined with Dabrafenib.
Didanosine	The excretion of Didanosine can be decreased when combined with Dabrafenib.
Dienogest	The serum concentration of Dienogest can be decreased when it is combined with Dabrafenib.
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabrafenib.
Difluocortolone	The serum concentration of Difluocortolone can be decreased when it is combined with Dabrafenib.
Difluprednate	The serum concentration of Difluprednate can be decreased when it is combined with Dabrafenib.
Digitoxin	The serum concentration of Digitoxin can be decreased when it is combined with Dabrafenib.
Digoxin	The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dabrafenib.
Dihydro-alpha	The serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Dabrafenib.
Dihydrocodeine	The serum concentration of Dihydrocodeine can be decreased when it is combined with Dabrafenib.
Dihydroergocornine	The serum concentration of Dihydroergocornine can be decreased when it is combined with Dabrafenib.
Dihydroergocristine	The serum concentration of Dihydroergocristine can be decreased when it is combined with Dabrafenib.
Dihydroergotamine	The serum concentration of Dihydroergotamine can be decreased when it is combined with Dabrafenib.
Diltiazem	The serum concentration of Diltiazem can be decreased when it is combined with Dabrafenib.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Dimenhydrinate.
Dimethyl sulfoxide	The metabolism of Dabrafenib can be decreased when combined with Dimethyl sulfoxide.
Dinoprostone	The excretion of Dinoprostone can be decreased when combined with Dabrafenib.
Diosmin	The serum concentration of Dabrafenib can be increased when it is combined with Diosmin.
Diphenhydramine	The serum concentration of Diphenhydramine can be decreased when it is combined with Dabrafenib.
Disopyramide	The serum concentration of Disopyramide can be decreased when it is combined with Dabrafenib.
Disulfiram	The serum concentration of Disulfiram can be decreased when it is combined with Dabrafenib.
Docetaxel	The serum concentration of Docetaxel can be decreased when it is combined with Dabrafenib.
Doconexent	The serum concentration of Doconexent can be decreased when it is combined with Dabrafenib.
Dofetilide	The serum concentration of Dofetilide can be decreased when it is combined with Dabrafenib.
Dolasetron	The serum concentration of Dolasetron can be decreased when it is combined with Dabrafenib.
Dolutegravir	Dabrafenib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.
Domperidone	The serum concentration of Domperidone can be decreased when it is combined with Dabrafenib.
Donepezil	The serum concentration of Donepezil can be decreased when it is combined with Dabrafenib.
Dopamine	The serum concentration of Dopamine can be increased when it is combined with Dabrafenib.
Doravirine	The serum concentration of Doravirine can be decreased when it is combined with Dabrafenib.
Doripenem	The excretion of Doripenem can be decreased when combined with Dabrafenib.
Dosulepin	The serum concentration of Dosulepin can be decreased when it is combined with Dabrafenib.
Doxazosin	The serum concentration of Doxazosin can be decreased when it is combined with Dabrafenib.
Doxepin	The serum concentration of Doxepin can be decreased when it is combined with Dabrafenib.
Doxorubicin	The serum concentration of Doxorubicin can be decreased when it is combined with Dabrafenib.
Doxylamine	The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Dabrafenib.
Dronabinol	The serum concentration of Dronabinol can be decreased when it is combined with Dabrafenib.
Dronedarone	The serum concentration of Dabrafenib can be increased when it is combined with Dronedarone.
Droperidol	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Droperidol.
Drospirenone	The serum concentration of Drospirenone can be decreased when it is combined with Dabrafenib.
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Dabrafenib.
Duloxetine	The serum concentration of Duloxetine can be decreased when it is combined with Dabrafenib.
Duvelisib	The serum concentration of Duvelisib can be decreased when it is combined with Dabrafenib.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Dyclonine.
Dydrogesterone	The serum concentration of Dydrogesterone can be decreased when it is combined with Dabrafenib.
Ebastine	The serum concentration of Ebastine can be decreased when it is combined with Dabrafenib.
Echinacea	The metabolism of Dabrafenib can be increased when combined with Echinacea.
Econazole	The serum concentration of Dabrafenib can be increased when it is combined with Econazole.
Edoxaban	The serum concentration of Dabrafenib can be increased when it is combined with Edoxaban.
Efavirenz	The serum concentration of Dabrafenib can be increased when it is combined with Efavirenz.
Elagolix	The serum concentration of Elagolix can be decreased when it is combined with Dabrafenib.
Elbasvir	The serum concentration of Elbasvir can be decreased when it is combined with Dabrafenib.
Eletriptan	The serum concentration of Eletriptan can be decreased when it is combined with Dabrafenib.
Elexacaftor	The serum concentration of Elexacaftor can be decreased when it is combined with Dabrafenib.
Eliglustat	The metabolism of Eliglustat can be decreased when combined with Dabrafenib.
Eltrombopag	The serum concentration of Eltrombopag can be decreased when it is combined with Dabrafenib.
Eluxadoline	The serum concentration of Eluxadoline can be increased when it is combined with Dabrafenib.
Elvitegravir	The serum concentration of Dabrafenib can be increased when it is combined with Elvitegravir.
Emapalumab	The metabolism of Dabrafenib can be increased when combined with Emapalumab.
Emedastine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Emedastine.
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.
Enalapril	The excretion of Enalapril can be decreased when combined with Dabrafenib.
Enasidenib	The serum concentration of Enasidenib can be decreased when it is combined with Dabrafenib.
Encainide	The risk or severity of QTc prolongation can be increased when Encainide is combined with Dabrafenib.
Encorafenib	The serum concentration of Encorafenib can be decreased when it is combined with Dabrafenib.
Enfortumab vedotin	The serum concentration of Enfortumab vedotin can be decreased when it is combined with Dabrafenib.
Enoxacin	The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Dabrafenib.
Entrectinib	The metabolism of Entrectinib can be increased when combined with Dabrafenib.
Enzalutamide	The serum concentration of Enzalutamide can be increased when it is combined with Dabrafenib.
Epinastine	The serum concentration of Epinastine can be decreased when it is combined with Dabrafenib.
Epinephrine	The metabolism of Dabrafenib can be decreased when combined with Epinephrine.
Eplerenone	The serum concentration of Eplerenone can be decreased when it is combined with Dabrafenib.
Eravacycline	The serum concentration of Eravacycline can be decreased when it is combined with Dabrafenib.
Erdafitinib	The metabolism of Erdafitinib can be increased when combined with Dabrafenib.
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib.
Ergometrine	The serum concentration of Ergometrine can be decreased when it is combined with Dabrafenib.
Ergotamine	The serum concentration of Dabrafenib can be increased when it is combined with Ergotamine.
Eribulin	The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dabrafenib.
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Dabrafenib.
Ertugliflozin	The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Dabrafenib.
Erythromycin	The serum concentration of Erythromycin can be decreased when it is combined with Dabrafenib.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dabrafenib.
Escitalopram	The serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib.
Esketamine	The serum concentration of Esketamine can be decreased when it is combined with Dabrafenib.
Eslicarbazepine	The metabolism of Dabrafenib can be increased when combined with Eslicarbazepine.
Eslicarbazepine	The metabolism of Dabrafenib can be increased when combined with Eslicarbazepine acetate.
Esmolol	The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dabrafenib.
Esomeprazole	The serum concentration of Esomeprazole can be decreased when it is combined with Dabrafenib.
Estazolam	The serum concentration of Estazolam can be decreased when it is combined with Dabrafenib.
Esterified estrogens	The serum concentration of Esterified estrogens can be decreased when it is combined with Dabrafenib.
Estetrol	The serum concentration of Estetrol can be decreased when it is combined with Dabrafenib.
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Dabrafenib.
Estradiol acetate	The serum concentration of Estradiol acetate can be decreased when it is combined with Dabrafenib.
Estradiol benzoate	The serum concentration of Estradiol benzoate can be decreased when it is combined with Dabrafenib.
Estradiol cypionate	The serum concentration of Estradiol cypionate can be decreased when it is combined with Dabrafenib.
Estradiol dienanthate	The serum concentration of Estradiol dienanthate can be decreased when it is combined with Dabrafenib.
Estradiol valerate	The serum concentration of Estradiol valerate can be decreased when it is combined with Dabrafenib.

Estramustine	The serum concentration of Estramustine can be decreased when it is combined with Dabrafenib.
Estrone	The serum concentration of Estrone can be decreased when it is combined with Dabrafenib.
Estrone sulfate	The serum concentration of Estrone sulfate can be decreased when it is combined with Dabrafenib.
Eszopiclone	The serum concentration of Eszopiclone can be decreased when it is combined with Dabrafenib.
Etanercept	The metabolism of Dabrafenib can be increased when combined with Etanercept.
Ethambutol	The metabolism of Dabrafenib can be decreased when combined with Ethambutol.
Ethanol	The serum concentration of Ethanol can be decreased when it is combined with Dabrafenib.
Ethinylestradiol	The serum concentration of Ethinylestradiol can be decreased when it is combined with Dabrafenib.
Ethosuximide	The serum concentration of Ethosuximide can be decreased when it is combined with Dabrafenib.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Ethyl chloride.
Ethynodiol	The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Dabrafenib.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Etidocaine.
Etodolac	The serum concentration of Etodolac can be decreased when it is combined with Dabrafenib.
Etonogestrel	The serum concentration of Etonogestrel can be decreased when it is combined with Dabrafenib.
Etoposide	The serum concentration of Etoposide can be decreased when it is combined with Dabrafenib.
Etoricoxib	The serum concentration of Etoricoxib can be decreased when it is combined with Dabrafenib.
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Dabrafenib.
Everolimus	The serum concentration of Everolimus can be decreased when it is combined with Dabrafenib.
Exemestane	The serum concentration of Exemestane can be decreased when it is combined with Dabrafenib.
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Dabrafenib.
Ezetimibe	Dabrafenib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.
Ezogabine	The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Dabrafenib.
Famotidine	Famotidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Favipiravir	The serum concentration of Dabrafenib can be increased when it is combined with Favipiravir.
Febuxostat	The excretion of Dabrafenib can be decreased when combined with Febuxostat.
Fedratinib	The serum concentration of Fedratinib can be decreased when it is combined with Dabrafenib.
Felbamate	The serum concentration of Felbamate can be decreased when it is combined with Dabrafenib.
Felodipine	The serum concentration of Dabrafenib can be increased when it is combined with Felodipine.
Fenfluramine	The serum concentration of Fenfluramine can be decreased when it is combined with Dabrafenib.
Fenofibrate	The serum concentration of Fenofibrate can be decreased when it is combined with Dabrafenib.
Fentanyl	The metabolism of Fentanyl can be decreased when combined with Dabrafenib.
Fesoterodine	The serum concentration of Fesoterodine can be decreased when it is combined with Dabrafenib.
Fexinidazole	The serum concentration of Fexinidazole can be decreased when it is combined with Dabrafenib.
Fexofenadine	The excretion of Fexofenadine can be decreased when combined with Dabrafenib.
Filgotinib	The serum concentration of Dabrafenib can be increased when it is combined with Filgotinib.
Finasteride	The serum concentration of Finasteride can be decreased when it is combined with Dabrafenib.
Finerenone	The serum concentration of Finerenone can be increased when it is combined with Dabrafenib.
Fish oil	The serum concentration of Fish oil can be decreased when it is combined with Dabrafenib.
Flecainide	The metabolism of Dabrafenib can be decreased when combined with Flecainide.
Flibanserin	The serum concentration of Flibanserin can be decreased when it is combined with Dabrafenib.
Floxuridine	The metabolism of Dabrafenib can be decreased when combined with Floxuridine.
Flucloxacillin	The metabolism of Dabrafenib can be increased when combined with Flucloxacillin.
Fluconazole	The serum concentration of Dabrafenib can be increased when it is combined with Fluconazole.
Fludrocortisone	The serum concentration of Fludrocortisone can be decreased when it is combined with Dabrafenib.
Fluindione	The serum concentration of Fluindione can be decreased when it is combined with Dabrafenib.
Flumethasone	The serum concentration of Flumethasone can be decreased when it is combined with Dabrafenib.
Flunarizine	The serum concentration of Flunarizine can be decreased when it is combined with Dabrafenib.
Flunisolide	The serum concentration of Flunisolide can be decreased when it is combined with Dabrafenib.
Flunitrazepam	The serum concentration of Flunitrazepam can be decreased when it is combined with Dabrafenib.
Fluocinolone acetonide	The serum concentration of Fluocinolone acetonide can be decreased when it is combined with Dabrafenib.
Fluocinonide	The serum concentration of Fluocinonide can be decreased when it is combined with Dabrafenib.
Fluocortolone	The serum concentration of Fluocortolone can be decreased when it is combined with Dabrafenib.
Fluorescein	The excretion of Fluorescein can be decreased when combined with Dabrafenib.
Fluorometholone	The serum concentration of Fluorometholone can be decreased when it is combined with Dabrafenib.
Fluorouracil	The serum concentration of Fluorouracil can be decreased when it is combined with Dabrafenib.
Fluoxetine	The serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib.
Flupentixol	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Flupentixol.
Fluprednisolone	The serum concentration of Fluprednisolone can be decreased when it is combined with Dabrafenib.
Flurandrenolide	The serum concentration of Flurandrenolide can be decreased when it is combined with Dabrafenib.
Flurazepam	The serum concentration of Flurazepam can be decreased when it is combined with Dabrafenib.
Flurbiprofen	The serum concentration of Flurbiprofen can be decreased when it is combined with Dabrafenib.
Fluspirilene	The serum concentration of Fluspirilene can be decreased when it is combined with Dabrafenib.
Flutamide	The serum concentration of Flutamide can be decreased when it is combined with Dabrafenib.
Fluticasone	The serum concentration of Dabrafenib can be increased when it is combined with Fluticasone.
Fluticasone furoate	The serum concentration of Dabrafenib can be increased when it is combined with Fluticasone furoate.
Fluticasone propionate	The serum concentration of Dabrafenib can be increased when it is combined with Fluticasone propionate.
Fluvastatin	The serum concentration of Fluvastatin can be decreased when it is combined with Dabrafenib.
Fluvoxamine	The serum concentration of Fluvoxamine can be decreased when it is combined with Dabrafenib.
Folic acid	Dabrafenib may decrease the excretion rate of Folic acid which could result in a higher serum level.
Formestane	The metabolism of Dabrafenib can be increased when combined with Formestane.
Formoterol	The serum concentration of Formoterol can be decreased when it is combined with Dabrafenib.
Fosamprenavir	The serum concentration of Fosamprenavir can be decreased when it is combined with Dabrafenib.
Fosaprepitant	The serum concentration of Fosaprepitant can be decreased when it is combined with Dabrafenib.
Foscarnet	The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dabrafenib.
Fosnetupitant	The serum concentration of Fosnetupitant can be decreased when it is combined with Dabrafenib.
Fosphenytoin	The serum concentration of Fosphenytoin can be decreased when it is combined with Dabrafenib.
Fostamatinib	The serum concentration of Fostamatinib can be decreased when it is combined with Dabrafenib.
Fostemsavir	The serum concentration of Fostemsavir can be decreased when it is combined with Dabrafenib.
Fulvestrant	The metabolism of Fulvestrant can be decreased when combined with Dabrafenib.
Furosemide	The metabolism of Furosemide can be decreased when combined with Dabrafenib.
Fusidic acid	The serum concentration of Fusidic acid can be decreased when it is combined with Dabrafenib.
Futibatinib	The serum concentration of Futibatinib can be decreased when it is combined with Dabrafenib.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Gadobenic acid.
Gadoxetic acid	The excretion of Gadoxetic acid can be decreased when combined with Dabrafenib.
Galantamine	The serum concentration of Galantamine can be decreased when it is combined with Dabrafenib.
Gatifloxacin	The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Dabrafenib.
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Dabrafenib.
Gemcitabine	The serum concentration of Dabrafenib can be increased when it is combined with Gemcitabine.
Gemfibrozil	The serum concentration of Dabrafenib can be increased when it is combined with Gemfibrozil.
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Gemifloxacin.
Gentamicin	The serum concentration of Gentamicin can be increased when it is combined with Dabrafenib.
Gestrinone	The serum concentration of Gestrinone can be decreased when it is combined with Dabrafenib.
Gilteritinib	The serum concentration of Gilteritinib can be decreased when it is combined with Dabrafenib.
Ginkgo biloba	The metabolism of Dabrafenib can be decreased when combined with Ginkgo biloba.
Glasdegib	The serum concentration of Glasdegib can be decreased when it is combined with Dabrafenib.
Glecaprevir	The serum concentration of Dabrafenib can be increased when it is combined with Glecaprevir.
Gliclazide	The serum concentration of Gliclazide can be decreased when it is combined with Dabrafenib.
Glimepiride	The serum concentration of Glimepiride can be decreased when it is combined with Dabrafenib.
Glipizide	The serum concentration of Glipizide can be decreased when it is combined with Dabrafenib.
Gliquidone	The serum concentration of Gliquidone can be decreased when it is combined with Dabrafenib.

Glyburide	The serum concentration of Glyburide can be decreased when it is combined with Dabrafenib.
Glycerol phenylbutyrate	The metabolism of Dabrafenib can be increased when combined with Glycerol phenylbutyrate.
Glymidine	The therapeutic efficacy of Glymidine can be decreased when used in combination with Dabrafenib.
Golimumab	The metabolism of Dabrafenib can be increased when combined with Golimumab.
Goserelin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Goserelin.
Granisetron	The serum concentration of Granisetron can be decreased when it is combined with Dabrafenib.
Grazoprevir	The serum concentration of Grazoprevir can be decreased when it is combined with Dabrafenib.
Grepafloxacin	The serum concentration of Grepafloxacin can be decreased when it is combined with Dabrafenib.
Griseofulvin	The metabolism of Dabrafenib can be increased when combined with Griseofulvin.
Guanfacine	The serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib.
Halcinonide	The serum concentration of Halcinonide can be decreased when it is combined with Dabrafenib.
Halofantrine	The serum concentration of Halofantrine can be decreased when it is combined with Dabrafenib.
Haloperidol	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Haloperidol.
Halothane	The serum concentration of Halothane can be decreased when it is combined with Dabrafenib.
Histamine	The serum concentration of Histamine can be increased when it is combined with Dabrafenib.
Histrelin	The risk or severity of QTc prolongation can be increased when Histrelin is combined with Dabrafenib.
Hydralazine	The metabolism of Dabrafenib can be decreased when combined with Hydralazine.
Hydrochlorothiazide	The excretion of Hydrochlorothiazide can be decreased when combined with Dabrafenib.
Hydrocodone	The serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib.
Hydrocortamate	The metabolism of Dabrafenib can be increased when combined with Hydrocortamate.
Hydrocortisone	The serum concentration of Hydrocortisone can be decreased when it is combined with Dabrafenib.
Hydrocortisone acetate	The serum concentration of Hydrocortisone acetate can be decreased when it is combined with Dabrafenib.
Hydrocortisone	The serum concentration of Hydrocortisone butyrate can be decreased when it is combined with Dabrafenib.
Hydrocortisone	The serum concentration of Hydrocortisone cypionate can be decreased when it is combined with Dabrafenib.
Hydrocortisone	The serum concentration of Hydrocortisone phosphate can be decreased when it is combined with Dabrafenib.
Hydrocortisone	The serum concentration of Hydrocortisone probutate can be decreased when it is combined with Dabrafenib.
Hydrocortisone	The serum concentration of Hydrocortisone succinate can be decreased when it is combined with Dabrafenib.
Hydrocortisone	The serum concentration of Hydrocortisone valerate can be decreased when it is combined with Dabrafenib.
Hydromorphone	The serum concentration of Hydromorphone can be decreased when it is combined with Dabrafenib.
Hydrotalcite	Hydrotalcite can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hydroxychloroquine	The serum concentration of Hydroxychloroquine can be decreased when it is combined with Dabrafenib.
Hydroxyprogesterone	The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Dabrafenib.
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Hydroxyzine.
Hyoscyamine	The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Dabrafenib.
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dabrafenib.
Ibrexafungerp	The serum concentration of Ibrexafungerp can be decreased when it is combined with Dabrafenib.
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Dabrafenib.
Ibuprofen	The serum concentration of Ibuprofen can be decreased when it is combined with Dabrafenib.
Ibutilide	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ibutilide.
Idarubicin	The serum concentration of Idarubicin can be decreased when it is combined with Dabrafenib.
Idelalisib	The serum concentration of Idelalisib can be decreased when it is combined with Dabrafenib.
Ifosfamide	The metabolism of Ifosfamide can be increased when combined with Dabrafenib.
Iloperidone	The metabolism of Iloperidone can be decreased when combined with Dabrafenib.
Imatinib	The serum concentration of Imatinib can be decreased when it is combined with Dabrafenib.
Imipramine	The serum concentration of Imipramine can be decreased when it is combined with Dabrafenib.
Imiquimod	The serum concentration of Imiquimod can be decreased when it is combined with Dabrafenib.
Indacaterol	The serum concentration of Indacaterol can be decreased when it is combined with Dabrafenib.
Indapamide	The serum concentration of Indapamide can be decreased when it is combined with Dabrafenib.
Indinavir	The serum concentration of Dabrafenib can be increased when it is combined with Indinavir.
Indomethacin	The serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib.
Infigratinib	The serum concentration of Infigratinib can be decreased when it is combined with Dabrafenib.
Infliximab	The metabolism of Dabrafenib can be increased when combined with Infliximab.
Inotersen	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Inotersen.
Inotuzumab	The serum concentration of Dabrafenib can be increased when it is combined with Inotuzumab ozogamicin.
Insulin aspart	The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Dabrafenib.
Insulin beef	The therapeutic efficacy of Insulin beef can be decreased when used in combination with Dabrafenib.
Insulin degludec	The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Dabrafenib.
Insulin detemir	The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Dabrafenib.
Insulin glargine	The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Dabrafenib.
Insulin glulisine	The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Dabrafenib.
Insulin human	The therapeutic efficacy of Insulin human can be decreased when used in combination with Dabrafenib.
Insulin lispro	The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Dabrafenib.
Insulin pork	The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dabrafenib.
Ipecac	The serum concentration of Ipecac can be decreased when it is combined with Dabrafenib.
Irbesartan	The serum concentration of Irbesartan can be decreased when it is combined with Dabrafenib.
Irinotecan	The risk or severity of neutropenia can be increased when Dabrafenib is combined with Irinotecan.
Isavuconazole	The serum concentration of Isavuconazole can be decreased when it is combined with Dabrafenib.
Isavuconazonium	The serum concentration of Isavuconazonium can be decreased when it is combined with Dabrafenib.
Isoflurane	The serum concentration of Isoflurane can be decreased when it is combined with Dabrafenib.
Isoniazid	The metabolism of Dabrafenib can be decreased when combined with Isoniazid.
Isotretinoin	The serum concentration of Isotretinoin can be decreased when it is combined with Dabrafenib.
Isradipine	The serum concentration of Isradipine can be decreased when it is combined with Dabrafenib.
Istradefylline	The serum concentration of Istradefylline can be decreased when it is combined with Dabrafenib.
Itraconazole	The serum concentration of Dabrafenib can be increased when it is combined with Itraconazole.
Ivabradine	The serum concentration of Ivabradine can be decreased when it is combined with Dabrafenib.
Ivacaftor	The serum concentration of Ivacaftor can be decreased when it is combined with Dabrafenib.
Ivermectin	The serum concentration of Ivermectin can be decreased when it is combined with Dabrafenib.
Ivosidenib	The metabolism of Dabrafenib can be increased when combined with Ivosidenib.
Ixabepilone	The serum concentration of Ixabepilone can be decreased when it is combined with Dabrafenib.
Ixazomib	The serum concentration of Ixazomib can be decreased when it is combined with Dabrafenib.
Ketamine	The serum concentration of Ketamine can be decreased when it is combined with Dabrafenib.
Ketazolam	The serum concentration of Ketazolam can be decreased when it is combined with Dabrafenib.
Ketoconazole	The serum concentration of Dabrafenib can be increased when it is combined with Ketoconazole.
Ketoprofen	The metabolism of Dabrafenib can be decreased when combined with Ketoprofen.
Ketorolac	The serum concentration of Ketorolac can be decreased when it is combined with Dabrafenib.
Labetalol	The serum concentration of Labetalol can be decreased when it is combined with Dabrafenib.
Lacidipine	The serum concentration of Lacidipine can be decreased when it is combined with Dabrafenib.
Lacosamide	The serum concentration of Lacosamide can be decreased when it is combined with Dabrafenib.
Lamivudine	Dabrafenib may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Lamotrigine	The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Dabrafenib.
Lanreotide	The metabolism of Dabrafenib can be decreased when combined with Lanreotide.
Lansoprazole	The serum concentration of Lansoprazole can be decreased when it is combined with Dabrafenib.
Lapatinib	The serum concentration of Lapatinib can be decreased when it is combined with Dabrafenib.
Larotrectinib	The serum concentration of Larotrectinib can be decreased when it is combined with Dabrafenib.
Lasmiditan	The serum concentration of Dabrafenib can be increased when it is combined with Lasmiditan.
Ledipasvir	The serum concentration of Dabrafenib can be increased when it is combined with Ledipasvir.
Lefamulin	Lefamulin may increase the QTc-prolonging activities of Dabrafenib.
Leflunomide	The serum concentration of Leflunomide can be decreased when it is combined with Dabrafenib.
Lemborexant	The serum concentration of Lemborexant can be increased when it is combined with Dabrafenib.
Lenvatinib	Dabrafenib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.

Lercanidipine	The serum concentration of Lercanidipine can be decreased when it is combined with Dabrafenib.
Lesinurad	The serum concentration of Lesinurad can be decreased when it is combined with Dabrafenib.
Letermovir	The metabolism of Dabrafenib can be decreased when combined with Letermovir.
Letrozole	The serum concentration of Letrozole can be decreased when it is combined with Dabrafenib.
Leucovorin	The excretion of Leucovorin can be decreased when combined with Dabrafenib.
Leuprolide	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Leuprolide.
Levacetylmethadol	The serum concentration of Levacetylmethadol can be decreased when it is combined with Dabrafenib.
Levamlodipine	The serum concentration of Levamlodipine can be increased when it is combined with Dabrafenib.
Levobupivacaine	The serum concentration of Levobupivacaine can be decreased when it is combined with Dabrafenib.
Levocabastine	The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Dabrafenib.
Levocarnitine	The excretion of Levocarnitine can be decreased when combined with Dabrafenib.
Levocetirizine	The serum concentration of Levocetirizine can be decreased when it is combined with Dabrafenib.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Levofloxacin.
Levoketoconazole	The serum concentration of Dabrafenib can be increased when it is combined with Levoketoconazole.
Levomenthol	The serum concentration of Levomenthol can be decreased when it is combined with Dabrafenib.
Levomilnacipran	The serum concentration of Levomilnacipran can be decreased when it is combined with Dabrafenib.
Levonorgestrel	The serum concentration of Levonorgestrel can be decreased when it is combined with Dabrafenib.
Levosalbutamol	The excretion of Levosalbutamol can be decreased when combined with Dabrafenib.
Levosimendan	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Levosimendan.
Levothyroxine	The serum concentration of Dabrafenib can be decreased when it is combined with Levothyroxine.
Lidocaine	The serum concentration of Lidocaine can be decreased when it is combined with Dabrafenib.
Lidoflazine	The serum concentration of Lidoflazine can be decreased when it is combined with Dabrafenib.
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Dabrafenib.
Linzagolix	The serum concentration of Dabrafenib can be increased when it is combined with Linzagolix.
Liothyronine	The metabolism of Liothyronine can be decreased when combined with Dabrafenib.
Liotrix	The serum concentration of Liotrix can be decreased when it is combined with Dabrafenib.
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Dabrafenib.
Lisuride	The serum concentration of Lisuride can be decreased when it is combined with Dabrafenib.
Lixisenatide	The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Dabrafenib.
Lofexidine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Lofexidine.
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Lomefloxacin.
Lomitapide	The serum concentration of Lomitapide can be decreased when it is combined with Dabrafenib.
Lonafarnib	The serum concentration of Lonafarnib can be increased when it is combined with Dabrafenib.
Loncastuximab	The serum concentration of Dabrafenib can be increased when it is combined with Loncastuximab tesirine.
Loperamide	The serum concentration of Loperamide can be decreased when it is combined with Dabrafenib.
Lopinavir	The serum concentration of Dabrafenib can be increased when it is combined with Lopinavir.
Loratadine	The serum concentration of Loratadine can be decreased when it is combined with Dabrafenib.
Lorazepam	The serum concentration of Lorazepam can be decreased when it is combined with Dabrafenib.
Lorcaserin	The serum concentration of Lorcaserin can be decreased when it is combined with Dabrafenib.
Lorlatinib	The serum concentration of Lorlatinib can be decreased when it is combined with Dabrafenib.
Lornoxicam	The serum concentration of Lornoxicam can be decreased when it is combined with Dabrafenib.
Lorpiprazole	The serum concentration of Lorpiprazole can be decreased when it is combined with Dabrafenib.
Losartan	The serum concentration of Losartan can be decreased when it is combined with Dabrafenib.
Lovastatin	The metabolism of Lovastatin can be decreased when combined with Dabrafenib.
Loxapine	The serum concentration of Dabrafenib can be increased when it is combined with Loxapine.
Lumacaftor	The serum concentration of Dabrafenib can be decreased when it is combined with Lumacaftor.
Lumateperone	The serum concentration of Lumateperone can be decreased when it is combined with Dabrafenib.
Lumefantrine	The serum concentration of Lumefantrine can be decreased when it is combined with Dabrafenib.
Lumiracoxib	The serum concentration of Lumiracoxib can be decreased when it is combined with Dabrafenib.
Lurasidone	The serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib.
Lurbinectedin	The serum concentration of Lurbinectedin can be decreased when it is combined with Dabrafenib.
Lusutrombopag	Dabrafenib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.
Lynestrenol	The serum concentration of Lynestrenol can be decreased when it is combined with Dabrafenib.
Macimorelin	The serum concentration of Macimorelin can be decreased when it is combined with Dabrafenib.
Macitentan	The serum concentration of Macitentan can be decreased when it is combined with Dabrafenib.
Magaldrate	Magaldrate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonate	Magnesium carbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxide	Magnesium hydroxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxide	Magnesium oxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium silicate	Magnesium silicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium trisilicate	Magnesium trisilicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Malathion	The serum concentration of Malathion can be decreased when it is combined with Dabrafenib.
Manidipine	The serum concentration of Manidipine can be decreased when it is combined with Dabrafenib.
Mannitol	The serum concentration of Dabrafenib can be increased when it is combined with Mannitol.
Maprotiline	The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dabrafenib.
Maraviroc	The serum concentration of Maraviroc can be decreased when it is combined with Dabrafenib.
Maribavir	The serum concentration of Maribavir can be decreased when it is combined with Dabrafenib.
Mavacamten	The serum concentration of Mavacamten can be decreased when it is combined with Dabrafenib.
Mecasermin	The therapeutic efficacy of Mecasermin can be decreased when used in combination with Dabrafenib.
Medrogestone	The serum concentration of Medrogestone can be decreased when it is combined with Dabrafenib.
Medroxyprogesterone	The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dabrafenib.
Medrysone	The serum concentration of Medrysone can be decreased when it is combined with Dabrafenib.
Mefenamic acid	The serum concentration of Mefenamic acid can be decreased when it is combined with Dabrafenib.
Mefloquine	The serum concentration of Mefloquine can be decreased when it is combined with Dabrafenib.
Megestrol acetate	The serum concentration of Megestrol acetate can be decreased when it is combined with Dabrafenib.
Meloxicam	The serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib.
Memantine	The serum concentration of Memantine can be increased when it is combined with Dabrafenib.
Meperidine	The serum concentration of Meperidine can be decreased when it is combined with Dabrafenib.
Mephenytoin	The serum concentration of Mephenytoin can be decreased when it is combined with Dabrafenib.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Mepivacaine.
Meprednisone	The serum concentration of Meprednisone can be decreased when it is combined with Dabrafenib.
Mepyramine	The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Dabrafenib.
Mercaptopurine	The excretion of Mercaptopurine can be decreased when combined with Dabrafenib.
Mesoridazine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mesoridazine.
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Dabrafenib.
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib.
Methadone	The serum concentration of Methadone can be decreased when it is combined with Dabrafenib.
Methantheline	Methantheline can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methimazole	The serum concentration of Dabrafenib can be increased when it is combined with Methimazole.
Methotrexate	The serum concentration of Methotrexate can be decreased when it is combined with Dabrafenib.
Methotrimeprazine	The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Dabrafenib.
Methoxy	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dabrafenib.
Methoxyflurane	The serum concentration of Methoxyflurane can be decreased when it is combined with Dabrafenib.
Methsuximide	The serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib.
Methylene blue	The serum concentration of Methylene blue can be decreased when it is combined with Dabrafenib.
Methylergometrine	The serum concentration of Methylergometrine can be decreased when it is combined with Dabrafenib.
Methylphenobarbital	The serum concentration of Methylphenobarbital can be decreased when it is combined with Dabrafenib.
Methylprednisolone	The serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib.
Methylprednisone	The serum concentration of Methylprednisone can be decreased when it is combined with Dabrafenib.
Methyltestosterone	The serum concentration of Methyltestosterone can be decreased when it is combined with Dabrafenib.

Methysergide	The serum concentration of Methysergide can be decreased when it is combined with Dabrafenib.
Metoclopramide	The serum concentration of Metoclopramide can be decreased when it is combined with Dabrafenib.
Metreleptin	The metabolism of Dabrafenib can be increased when combined with Metreleptin.
Metronidazole	The metabolism of Dabrafenib can be decreased when combined with Metronidazole.
Metyrapone	The metabolism of Dabrafenib can be increased when combined with Metyrapone.
Mexiletine	The serum concentration of Mexiletine can be decreased when it is combined with Dabrafenib.
Mianserin	The serum concentration of Mianserin can be decreased when it is combined with Dabrafenib.
Miconazole	The metabolism of Dabrafenib can be decreased when combined with Miconazole.
Midazolam	The serum concentration of Midazolam can be decreased when it is combined with Dabrafenib.
Midostaurin	The serum concentration of Dabrafenib can be increased when it is combined with Midostaurin.
Mifepristone	The serum concentration of Dabrafenib can be increased when it is combined with Mifepristone.
Migalastat	The metabolism of Migalastat can be decreased when combined with Dabrafenib.
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Dabrafenib.
Milnacipran	The serum concentration of Milnacipran can be decreased when it is combined with Dabrafenib.
Minoxidil	The metabolism of Minoxidil can be decreased when combined with Dabrafenib.
Miocamycin	The metabolism of Dabrafenib can be decreased when combined with Miocamycin.
Mirabegron	The serum concentration of Mirabegron can be decreased when it is combined with Dabrafenib.
Mirtazapine	The serum concentration of Mirtazapine can be decreased when it is combined with Dabrafenib.
Mitapivat	The serum concentration of Mitapivat can be decreased when it is combined with Dabrafenib.
Mitotane	The serum concentration of Dabrafenib can be decreased when it is combined with Mitotane.
Mitoxantrone	Dabrafenib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.
Mizolastine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mizolastine.
Mobocertinib	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Mobocertinib.
Moclobemide	The serum concentration of Moclobemide can be decreased when it is combined with Dabrafenib.
Modafinil	The serum concentration of Modafinil can be decreased when it is combined with Dabrafenib.
Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Dabrafenib.
Mometasone furoate	The serum concentration of Dabrafenib can be increased when it is combined with Mometasone furoate.
Montelukast	The serum concentration of Montelukast can be decreased when it is combined with Dabrafenib.
Moricizine	The risk or severity of QTc prolongation can be increased when Moricizine is combined with Dabrafenib.
Morphine	The serum concentration of Morphine can be decreased when it is combined with Dabrafenib.
Mosunetuzumab	The metabolism of Dabrafenib can be decreased when combined with Mosunetuzumab.
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Moxifloxacin.
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dabrafenib.
Mycophenolic acid	The metabolism of Mycophenolic acid can be decreased when combined with Dabrafenib.
Nabilone	The serum concentration of Nabilone can be decreased when it is combined with Dabrafenib.
Nabumetone	The serum concentration of Nabumetone can be decreased when it is combined with Dabrafenib.
Nafcillin	The metabolism of Dabrafenib can be increased when combined with Nafcillin.
Nalidixic acid	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Nalidixic acid.
Naloxegol	The serum concentration of Naloxegol can be decreased when it is combined with Dabrafenib.
Naloxone	The serum concentration of Dabrafenib can be increased when it is combined with Naloxone.
Naltrexone	The metabolism of Naltrexone can be decreased when combined with Dabrafenib.
Naproxen	The serum concentration of Naproxen can be decreased when it is combined with Dabrafenib.
Nateglinide	The serum concentration of Nateglinide can be decreased when it is combined with Dabrafenib.
Nebivolol	The serum concentration of Nebivolol can be decreased when it is combined with Dabrafenib.
Nefazodone	The serum concentration of Dabrafenib can be increased when it is combined with Nefazodone.
Nelfinavir	The serum concentration of Dabrafenib can be increased when it is combined with Nelfinavir.
Neratinib	The serum concentration of Neratinib can be decreased when it is combined with Dabrafenib.
Netupitant	The serum concentration of Netupitant can be decreased when it is combined with Dabrafenib.
Nevirapine	The serum concentration of Nevirapine can be decreased when it is combined with Dabrafenib.
Niacin	The metabolism of Dabrafenib can be decreased when combined with Niacin.
Nicardipine	The serum concentration of Nicardipine can be decreased when it is combined with Dabrafenib.
Niclosamide	The serum concentration of Niclosamide can be decreased when it is combined with Dabrafenib.
Nicotine	The serum concentration of Nicotine can be decreased when it is combined with Dabrafenib.
Nifedipine	The serum concentration of Nifedipine can be decreased when it is combined with Dabrafenib.
Nilotinib	The serum concentration of Dabrafenib can be increased when it is combined with Nilotinib.
Nilutamide	The serum concentration of Nilutamide can be decreased when it is combined with Dabrafenib.
Nilvadipine	The serum concentration of Nilvadipine can be decreased when it is combined with Dabrafenib.
Nimesulide	The serum concentration of Nimesulide can be decreased when it is combined with Dabrafenib.
Nimodipine	The serum concentration of Nimodipine can be decreased when it is combined with Dabrafenib.
Nintedanib	The serum concentration of Nintedanib can be decreased when it is combined with Dabrafenib.
Nirmatrelvir	The serum concentration of Nirmatrelvir can be decreased when it is combined with Dabrafenib.
Nisoldipine	The serum concentration of Nisoldipine can be decreased when it is combined with Dabrafenib.
Nitrazepam	The serum concentration of Nitrazepam can be decreased when it is combined with Dabrafenib.
Nitrendipine	The serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib.
Nitrofurantoin	Dabrafenib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Nizatidine	Nizatidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nomegestrol	The serum concentration of Nomegestrol can be decreased when it is combined with Dabrafenib.
Nomegestrol acetate	The serum concentration of Nomegestrol acetate can be decreased when it is combined with Dabrafenib.
Norelgestromin	The serum concentration of Norelgestromin can be decreased when it is combined with Dabrafenib.
Norepinephrine	The serum concentration of Norepinephrine can be increased when it is combined with Dabrafenib.
Norethisterone	The serum concentration of Norethisterone can be decreased when it is combined with Dabrafenib.
Norethynodrel	The serum concentration of Norethynodrel can be decreased when it is combined with Dabrafenib.
Norfloxacin	The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Dabrafenib.
Norgestimate	The serum concentration of Norgestimate can be decreased when it is combined with Dabrafenib.
Norgestrel	The serum concentration of Norgestrel can be decreased when it is combined with Dabrafenib.
Nortriptyline	The serum concentration of Nortriptyline can be decreased when it is combined with Dabrafenib.
Noscapine	The metabolism of Dabrafenib can be decreased when combined with Noscapine.
Novobiocin	Novobiocin may decrease the excretion rate of Dabrafenib which could result in a higher serum level.
Nylidrin	The serum concentration of Nylidrin can be decreased when it is combined with Dabrafenib.
Octreotide	The serum concentration of Dabrafenib can be increased when it is combined with Octreotide.
Ofloxacin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ofloxacin.
Olanzapine	Olanzapine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Olaparib	The serum concentration of Olaparib can be decreased when it is combined with Dabrafenib.
Oliceridine	The serum concentration of Oliceridine can be decreased when it is combined with Dabrafenib.
Olodaterol	The serum concentration of Olodaterol can be decreased when it is combined with Dabrafenib.
Omadacycline	The serum concentration of Dabrafenib can be increased when it is combined with Omadacycline.
Ombitasvir	The serum concentration of Ombitasvir can be decreased when it is combined with Dabrafenib.
Omeprazole	The serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib.
Ondansetron	The serum concentration of Ondansetron can be decreased when it is combined with Dabrafenib.
Opium	The serum concentration of Opium can be decreased when it is combined with Dabrafenib.
Oritavancin	The metabolism of Dabrafenib can be increased when combined with Oritavancin.
Orphenadrine	The serum concentration of Orphenadrine can be decreased when it is combined with Dabrafenib.
Oseltamivir	The excretion of Oseltamivir can be decreased when combined with Dabrafenib.
Osilodrostat	The serum concentration of Osilodrostat can be decreased when it is combined with Dabrafenib.
Osimertinib	The serum concentration of Osimertinib can be decreased when it is combined with Dabrafenib.
Ospemifene	The serum concentration of Ospemifene can be decreased when it is combined with Dabrafenib.
Oteseconazole	The serum concentration of Dabrafenib can be increased when it is combined with Oteseconazole.
Ouabain	The excretion of Ouabain can be decreased when combined with Dabrafenib.
Oxaliplatin	The serum concentration of Oxaliplatin can be increased when it is combined with Dabrafenib.
Oxandrolone	The metabolism of Dabrafenib can be decreased when combined with Oxandrolone.

Oxatomide	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Oxatomide.
Oxcarbazepine	The metabolism of Dabrafenib can be increased when combined with Oxcarbazepine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Oxetacaine.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Oxybuprocaine.
Oxybutynin	The serum concentration of Oxybutynin can be decreased when it is combined with Dabrafenib.
Oxycodone	The serum concentration of Oxycodone can be decreased when it is combined with Dabrafenib.
Oxymorphone	The serum concentration of Oxymorphone can be decreased when it is combined with Dabrafenib.
Oxytetracycline	The excretion of Oxytetracycline can be decreased when combined with Dabrafenib.
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dabrafenib.
Ozanimod	The metabolism of Ozanimod can be decreased when combined with Dabrafenib.
Paclitaxel	The serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib.
Pacritinib	The serum concentration of Dabrafenib can be increased when it is combined with Pacritinib.
Padeliporfin	Dabrafenib may increase the photosensitizing activities of Padeliporfin.
Palbociclib	The serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib.
Paliperidone	The serum concentration of Paliperidone can be decreased when it is combined with Dabrafenib.
Palonosetron	The serum concentration of Palonosetron can be decreased when it is combined with Dabrafenib.
Palovarotene	The serum concentration of Palovarotene can be decreased when it is combined with Dabrafenib.
Panobinostat	The serum concentration of Panobinostat can be decreased when it is combined with Dabrafenib.
Pantoprazole	The serum concentration of Pantoprazole can be decreased when it is combined with Dabrafenib.
Papaverine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Papaverine.
Paramethadione	The serum concentration of Paramethadione can be decreased when it is combined with Dabrafenib.
Parecoxib	The serum concentration of Parecoxib can be decreased when it is combined with Dabrafenib.
Paricalcitol	The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib.
Paritaprevir	The serum concentration of Paritaprevir can be decreased when it is combined with Dabrafenib.
Paroxetine	The serum concentration of Paroxetine can be decreased when it is combined with Dabrafenib.
Pasireotide	The metabolism of Dabrafenib can be decreased when combined with Pasireotide.
Pazopanib	The serum concentration of Pazopanib can be decreased when it is combined with Dabrafenib.
Pefloxacin	The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Dabrafenib.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Dabrafenib.
Peginterferon alfa-2b	The metabolism of Dabrafenib can be increased when combined with Peginterferon alfa-2b.
Pemetrexed	Dabrafenib may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Pemigatinib	The serum concentration of Pemigatinib can be decreased when it is combined with Dabrafenib.
Penicillamine	The excretion of Penicillamine can be decreased when combined with Dabrafenib.
Pentamidine	The serum concentration of Pentamidine can be decreased when it is combined with Dabrafenib.
Pentobarbital	The serum concentration of Pentobarbital can be decreased when it is combined with Dabrafenib.
Perampanel	The metabolism of Perampanel can be increased when combined with Dabrafenib.
Perflutren	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Perflutren.
Perhexiline	The serum concentration of Perhexiline can be decreased when it is combined with Dabrafenib.
Pexidartinib	The metabolism of Pexidartinib can be increased when combined with Dabrafenib.
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Dabrafenib.
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dabrafenib.
Phenobarbital	The serum concentration of Phenobarbital can be decreased when it is combined with Dabrafenib.
Phenol	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Phenol.
Phenprocoumon	The serum concentration of Phenprocoumon can be decreased when it is combined with Dabrafenib.
Phentermine	The serum concentration of Phentermine can be decreased when it is combined with Dabrafenib.
Phenylbutazone	The serum concentration of Phenylbutazone can be decreased when it is combined with Dabrafenib.
Phenytoin	The serum concentration of Phenytoin can be decreased when it is combined with Dabrafenib.
Pibrentasvir	The serum concentration of Dabrafenib can be increased when it is combined with Pibrentasvir.
Pimavanserin	The serum concentration of Pimavanserin can be decreased when it is combined with Dabrafenib.
Pimecrolimus	The serum concentration of Pimecrolimus can be decreased when it is combined with Dabrafenib.
Pimozide	The serum concentration of Pimozide can be decreased when it is combined with Dabrafenib.
Pinacidil	The serum concentration of Pinacidil can be decreased when it is combined with Dabrafenib.
Pinaverium	The serum concentration of Pinaverium can be decreased when it is combined with Dabrafenib.
Pioglitazone	The serum concentration of Pioglitazone can be increased when it is combined with Dabrafenib.
Piperacillin	The excretion of Piperacillin can be decreased when combined with Dabrafenib.
Piperaquine	The serum concentration of Piperaquine can be decreased when it is combined with Dabrafenib.
Pipotiazine	The serum concentration of Pipotiazine can be decreased when it is combined with Dabrafenib.
Pirfenidone	The serum concentration of Pirfenidone can be decreased when it is combined with Dabrafenib.
Piroxicam	The serum concentration of Piroxicam can be decreased when it is combined with Dabrafenib.
Pitavastatin	The serum concentration of Pitavastatin can be decreased when it is combined with Dabrafenib.
Pitolisant	The serum concentration of Dabrafenib can be decreased when it is combined with Pitolisant.
Polatuzumab	The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Dabrafenib.
Polythiazide	The excretion of Polythiazide can be decreased when combined with Dabrafenib.
Pomalidomide	The serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib.
Ponatinib	The serum concentration of Ponatinib can be decreased when it is combined with Dabrafenib.
Ponesimod	The risk or severity of bradycardia can be increased when Ponesimod is combined with Dabrafenib.
Porfimer sodium	Dabrafenib may increase the photosensitizing activities of Porfimer sodium.
Posaconazole	The serum concentration of Dabrafenib can be increased when it is combined with Posaconazole.
Pralatrexate	Dabrafenib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralsetinib	The serum concentration of Pralsetinib can be decreased when it is combined with Dabrafenib.
Pramipexole	The serum concentration of Pramipexole can be increased when it is combined with Dabrafenib.
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Dabrafenib.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Pramocaine.
Prasterone	The serum concentration of Prasterone can be decreased when it is combined with Dabrafenib.
Prasugrel	The serum concentration of Prasugrel can be decreased when it is combined with Dabrafenib.
Pravastatin	The excretion of Pravastatin can be decreased when combined with Dabrafenib.
Prazepam	The serum concentration of Prazepam can be decreased when it is combined with Dabrafenib.
Praziquantel	The serum concentration of Praziquantel can be decreased when it is combined with Dabrafenib.
Prazosin	Dabrafenib may decrease the excretion rate of Prazosin which could result in a higher serum level.
Prednicarbate	The serum concentration of Prednicarbate can be decreased when it is combined with Dabrafenib.
Prednisolone	The serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib.
Prednisolone	The serum concentration of Prednisolone acetate can be decreased when it is combined with Dabrafenib.
Prednisolone	The serum concentration of Prednisolone phosphate can be decreased when it is combined with Dabrafenib.
Prednisone	The serum concentration of Prednisone can be decreased when it is combined with Dabrafenib.
Prednisone acetate	The metabolism of Dabrafenib can be increased when combined with Prednisone acetate.
Pregabalin	The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Dabrafenib.
Pregnenolone	The serum concentration of Pregnenolone can be decreased when it is combined with Dabrafenib.
Prenylamine	The serum concentration of Prenylamine can be decreased when it is combined with Dabrafenib.
Pretomanid	The serum concentration of Pretomanid can be decreased when it is combined with Dabrafenib.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Prilocaine.
Primaquine	The serum concentration of Primaquine can be decreased when it is combined with Dabrafenib.
Primidone	The serum concentration of Primidone can be decreased when it is combined with Dabrafenib.
Probenecid	The metabolism of Dabrafenib can be increased when combined with Probenecid.
Probucol	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Probucol.
Procainamide	The serum concentration of Procainamide can be increased when it is combined with Dabrafenib.
Procaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Procaine.
Prochlorperazine	The serum concentration of Prochlorperazine can be decreased when it is combined with Dabrafenib.
Progesterone	The serum concentration of Progesterone can be decreased when it is combined with Dabrafenib.
Proguanil	The serum concentration of Proguanil can be decreased when it is combined with Dabrafenib.
Promazine	The serum concentration of Promazine can be decreased when it is combined with Dabrafenib.

Promethazine	The serum concentration of Promethazine can be decreased when it is combined with Dabrafenib.
Propafenone	The serum concentration of Propafenone can be decreased when it is combined with Dabrafenib.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Proparacaine.
Propiverine	The serum concentration of Propiverine can be decreased when it is combined with Dabrafenib.
Propofol	The serum concentration of Propofol can be decreased when it is combined with Dabrafenib.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Propoxycaine.
Propranolol	The serum concentration of Propranolol can be decreased when it is combined with Dabrafenib.
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Dabrafenib.
Prucalopride	The serum concentration of Prucalopride can be decreased when it is combined with Dabrafenib.
Pyrimethamine	The metabolism of Dabrafenib can be decreased when combined with Pyrimethamine.
Quazepam	The serum concentration of Quazepam can be decreased when it is combined with Dabrafenib.
Quetiapine	The serum concentration of Quetiapine can be decreased when it is combined with Dabrafenib.
Quinapril	The excretion of Quinapril can be decreased when combined with Dabrafenib.
Quinidine	The serum concentration of Quinidine can be decreased when it is combined with Dabrafenib.
Quinine	The serum concentration of Quinine can be decreased when it is combined with Dabrafenib.
Quinupristin	The metabolism of Dabrafenib can be decreased when combined with Quinupristin.
Rabeprazole	The serum concentration of Rabeprazole can be decreased when it is combined with Dabrafenib.
Raloxifene	The metabolism of Dabrafenib can be decreased when combined with Raloxifene.
Raltegravir	The metabolism of Raltegravir can be decreased when combined with Dabrafenib.
Ramelteon	The serum concentration of Ramelteon can be decreased when it is combined with Dabrafenib.
Ranitidine	Ranitidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ranolazine	The metabolism of Ranolazine can be increased when combined with Dabrafenib.
Reboxetine	The serum concentration of Reboxetine can be decreased when it is combined with Dabrafenib.
Regorafenib	The serum concentration of Regorafenib can be decreased when it is combined with Dabrafenib.
Relebactam	The excretion of Relebactam can be decreased when combined with Dabrafenib.
Relugolix	The serum concentration of Relugolix can be decreased when it is combined with Dabrafenib.
Remdesivir	The serum concentration of Remdesivir can be decreased when it is combined with Dabrafenib.
Repaglinide	The serum concentration of Repaglinide can be decreased when it is combined with Dabrafenib.
Reserpine	The serum concentration of Dabrafenib can be increased when it is combined with Reserpine.
Retapamulin	The metabolism of Retapamulin can be decreased when combined with Dabrafenib.
Revefenacin	Dabrafenib may decrease the excretion rate of Revefenacin which could result in a higher serum level.
Ribociclib	The serum concentration of Dabrafenib can be increased when it is combined with Ribociclib.
Rifabutin	The serum concentration of Rifabutin can be decreased when it is combined with Dabrafenib.
Rifampicin	The serum concentration of Dabrafenib can be decreased when it is combined with Rifampicin.
Rifamycin	The serum concentration of Dabrafenib can be decreased when it is combined with Rifamycin.
Rifapentine	The serum concentration of Rifapentine can be decreased when it is combined with Dabrafenib.
Rilonacept	The metabolism of Dabrafenib can be increased when combined with Rilonacept.
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Dabrafenib.
Riluzole	Dabrafenib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Rimegepant	The metabolism of Rimegepant can be increased when combined with Dabrafenib.
Rimexolone	The serum concentration of Rimexolone can be decreased when it is combined with Dabrafenib.
Rimonabant	The serum concentration of Rimonabant can be decreased when it is combined with Dabrafenib.
Riociguat	The serum concentration of Riociguat can be decreased when it is combined with Dabrafenib.
Ripretinib	The serum concentration of Ripretinib can be decreased when it is combined with Dabrafenib.
Risperidone	The serum concentration of Risperidone can be decreased when it is combined with Dabrafenib.
Ritonavir	The serum concentration of Dabrafenib can be increased when it is combined with Ritonavir.
Rivaroxaban	The serum concentration of Rivaroxaban can be decreased when it is combined with Dabrafenib.
Rofecoxib	The serum concentration of Rofecoxib can be decreased when it is combined with Dabrafenib.
Roflumilast	The serum concentration of Roflumilast can be decreased when it is combined with Dabrafenib.
Rolapitant	The serum concentration of Rolapitant can be decreased when it is combined with Dabrafenib.
Romidepsin	The serum concentration of Romidepsin can be decreased when it is combined with Dabrafenib.
Ropinirole	The risk or severity of adverse effects can be increased when Dabrafenib is combined with Ropinirole.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Ropivacaine.
Rosiglitazone	The serum concentration of Rosiglitazone can be decreased when it is combined with Dabrafenib.
Rosoxacin	The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Dabrafenib.
Rosuvastatin	The serum concentration of Rosuvastatin can be decreased when it is combined with Dabrafenib.
Rotigotine	The serum concentration of Rotigotine can be decreased when it is combined with Dabrafenib.
Roxadustat	The metabolism of Roxadustat can be decreased when combined with Dabrafenib.
Roxithromycin	The serum concentration of Roxithromycin can be decreased when it is combined with Dabrafenib.
Rucaparib	The serum concentration of Rucaparib can be decreased when it is combined with Dabrafenib.
Rufinamide	The metabolism of Dabrafenib can be increased when combined with Rufinamide.
Rupatadine	The serum concentration of Rupatadine can be decreased when it is combined with Dabrafenib.
Ruxolitinib	The serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib.
Sacituzumab govitecan	The serum concentration of Sacituzumab govitecan can be increased when it is combined with Dabrafenib.
Safinamide	The serum concentration of Safinamide can be decreased when it is combined with Dabrafenib.
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dabrafenib.
Salicylic acid	The serum concentration of Salicylic acid can be decreased when it is combined with Dabrafenib.
Salmeterol	The serum concentration of Dabrafenib can be increased when it is combined with Salmeterol.
Samidorphan	The serum concentration of Samidorphan can be decreased when it is combined with Dabrafenib.
Sapropterin	The serum concentration of Dabrafenib can be increased when it is combined with Sapropterin.
Saquinavir	The serum concentration of Dabrafenib can be increased when it is combined with Saquinavir.
Sarecycline	The serum concentration of Dabrafenib can be increased when it is combined with Sarecycline.
Sarilumab	The metabolism of Dabrafenib can be increased when combined with Sarilumab.
Satralizumab	The serum concentration of Dabrafenib can be decreased when it is combined with Satralizumab.
Saxagliptin	The serum concentration of Saxagliptin can be decreased when it is combined with Dabrafenib.
Scopolamine	The serum concentration of Scopolamine can be decreased when it is combined with Dabrafenib.
Secobarbital	The serum concentration of Dabrafenib can be decreased when it is combined with Secobarbital.
Secukinumab	The metabolism of Dabrafenib can be increased when combined with Secukinumab.
Segesterone	The metabolism of Segesterone acetate can be increased when combined with Dabrafenib.
Selegiline	The serum concentration of Selegiline can be decreased when it is combined with Dabrafenib.
Selexipag	The serum concentration of Selexipag can be decreased when it is combined with Dabrafenib.
Selinexor	The serum concentration of Selinexor can be decreased when it is combined with Dabrafenib.
Selpercatinib	The serum concentration of Selpercatinib can be increased when it is combined with Dabrafenib.
Selumetinib	The serum concentration of Selumetinib can be decreased when it is combined with Dabrafenib.
Semaglutide	The therapeutic efficacy of Semaglutide can be decreased when used in combination with Dabrafenib.
Sertindole	The serum concentration of Sertindole can be decreased when it is combined with Dabrafenib.
Sertraline	The serum concentration of Sertraline can be decreased when it is combined with Dabrafenib.
Sevoflurane	The serum concentration of Sevoflurane can be decreased when it is combined with Dabrafenib.
Sibutramine	The serum concentration of Sibutramine can be decreased when it is combined with Dabrafenib.
Sildenafil	The serum concentration of Sildenafil can be decreased when it is combined with Dabrafenib.
Silodosin	The serum concentration of Silodosin can be decreased when it is combined with Dabrafenib.
Siltuximab	The metabolism of Dabrafenib can be increased when combined with Siltuximab.
Simeprevir	The serum concentration of Simeprevir can be decreased when it is combined with Dabrafenib.
Simvastatin	The serum concentration of Simvastatin can be decreased when it is combined with Dabrafenib.
Sincalide	The excretion of Sincalide can be decreased when combined with Dabrafenib.
Siponimod	The serum concentration of Siponimod can be decreased when it is combined with Dabrafenib.
Sirolimus	The serum concentration of Sirolimus can be decreased when it is combined with Dabrafenib.
Sitagliptin	The serum concentration of Sitagliptin can be decreased when it is combined with Dabrafenib.
Sitaxentan	The serum concentration of Sitaxentan can be decreased when it is combined with Dabrafenib.
Sodium	Sodium bicarbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.

Solifenacin	The serum concentration of Solifenacin can be decreased when it is combined with Dabrafenib.
Solriamfetol	The serum concentration of Solriamfetol can be increased when it is combined with Dabrafenib.
Somatostatin	The metabolism of Dabrafenib can be decreased when combined with Somatostatin.
Somatrogon	The metabolism of Dabrafenib can be increased when combined with Somatrogon.
Sonidegib	The serum concentration of Sonidegib can be decreased when it is combined with Dabrafenib.
Sorafenib	The serum concentration of Dabrafenib can be increased when it is combined with Sorafenib.
Sotagliflozin	The serum concentration of Dabrafenib can be increased when it is combined with Sotagliflozin.
Sotalol	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sotalol.
Sotorasib	The serum concentration of Dabrafenib can be decreased when it is combined with Sotorasib.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sparfloxacin.
Spironolactone	The metabolism of Dabrafenib can be decreased when combined with Spironolactone.
St. John’s Wort	The serum concentration of St. John’s Wort can be decreased when it is combined with Dabrafenib.
Stavudine	The excretion of Stavudine can be decreased when combined with Dabrafenib.
Stiripentol	The metabolism of Dabrafenib can be decreased when combined with Stiripentol.
Succinic acid	The excretion of Succinic acid can be decreased when combined with Dabrafenib.
Sufentanil	The serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib.
Sulfadiazine	The serum concentration of Sulfadiazine can be decreased when it is combined with Dabrafenib.
Sulfamethizole	The metabolism of Dabrafenib can be decreased when combined with Sulfamethizole.
Sulfamethoxazole	The serum concentration of Sulfamethoxazole can be decreased when it is combined with Dabrafenib.
Sulfaphenazole	The metabolism of Dabrafenib can be decreased when combined with Sulfaphenazole.
Sulfapyridine	The metabolism of Dabrafenib can be decreased when combined with Sulfapyridine.
Sulfasalazine	Sulfasalazine may decrease the excretion rate of Dabrafenib which could result in a higher serum level.
Sulfinpyrazone	The serum concentration of Sulfinpyrazone can be decreased when it is combined with Dabrafenib.
Sulfisoxazole	The metabolism of Dabrafenib can be decreased when combined with Sulfisoxazole.
Sulpiride	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sulpiride.
Sultopride	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sultopride.
Sumatriptan	Dabrafenib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Sunitinib	The serum concentration of Sunitinib can be decreased when it is combined with Dabrafenib.
Suprofen	The serum concentration of Suprofen can be decreased when it is combined with Dabrafenib.
Suvorexant	The serum concentration of Suvorexant can be decreased when it is combined with Dabrafenib.
Estrogens, A	The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dabrafenib.
SEstrogens,	The serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Dabrafenib.
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Dabrafenib.
Tadalafil	The serum concentration of Tadalafil can be decreased when it is combined with Dabrafenib.
Tafamidis	The serum concentration of Dabrafenib can be increased when it is combined with Tafamidis.
Talazoparib	Dabrafenib may decrease the excretion rate of Talazoparib which could result in a higher serum level.
Tamoxifen	The serum concentration of Tamoxifen can be decreased when it is combined with Dabrafenib.
Tamsulosin	The serum concentration of Tamsulosin can be decreased when it is combined with Dabrafenib.
Tasimelteon	The serum concentration of Tasimelteon can be decreased when it is combined with Dabrafenib.
Taurocholic acid	The excretion of Taurocholic acid can be decreased when combined with Dabrafenib.
Tazarotene	The serum concentration of Tazarotene can be decreased when it is combined with Dabrafenib.
Tazemetostat	The serum concentration of Tazemetostat can be decreased when it is combined with Dabrafenib.
Tazobactam	The excretion of Tazobactam can be decreased when combined with Dabrafenib.
Technetium	The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Dabrafenib.
Technetium	The serum concentration of Dabrafenib can be increased when it is combined with Technetium Tc-99m sestamibi.
Tecovirimat	The metabolism of Dabrafenib can be increased when combined with Tecovirimat.
Tegafur	The serum concentration of Tegafur can be decreased when it is combined with Dabrafenib.
Tegaserod	The metabolism of Dabrafenib can be decreased when combined with Tegaserod.
Telaprevir	The serum concentration of Dabrafenib can be increased when it is combined with Telaprevir.
Telavancin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Telavancin.
Telithromycin	The serum concentration of Dabrafenib can be increased when it is combined with Telithromycin.
Telmisartan	Telmisartan may decrease the excretion rate of Dabrafenib which could result in a higher serum level.
Telotristat ethyl	The serum concentration of Dabrafenib can be decreased when it is combined with Telotristat ethyl.
Temsirolimus	The serum concentration of Temsirolimus can be decreased when it is combined with Dabrafenib.
Teniposide	The serum concentration of Teniposide can be decreased when it is combined with Dabrafenib.
Tenofovir alafenamide	The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Dabrafenib.
Tenofovir disoproxil	The excretion of Tenofovir disoproxil can be decreased when combined with Dabrafenib.
Tenoxicam	The serum concentration of Tenoxicam can be decreased when it is combined with Dabrafenib.
Tepotinib	The serum concentration of Dabrafenib can be increased when it is combined with Tepotinib.
Terbinafine	The serum concentration of Terbinafine can be decreased when it is combined with Dabrafenib.
Terbutaline	The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dabrafenib.
Terfenadine	The serum concentration of Dabrafenib can be increased when it is combined with Terfenadine.
Teriflunomide	The metabolism of Dabrafenib can be decreased when combined with Teriflunomide.
Terlipressin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Terlipressin.
Testosterone	The serum concentration of Testosterone can be decreased when it is combined with Dabrafenib.
Testosterone	The serum concentration of Testosterone cypionate can be decreased when it is combined with Dabrafenib.
Testosterone	The serum concentration of Testosterone enanthate can be decreased when it is combined with Dabrafenib.
Testosterone	The serum concentration of Testosterone propionate can be decreased when it is combined with Dabrafenib.
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Tetrabenazine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Dabrafenib is combined with Tetracaine.
Tetracycline	The serum concentration of Tetracycline can be decreased when it is combined with Dabrafenib.
Tezacaftor	The serum concentration of Tezacaftor can be decreased when it is combined with Dabrafenib.
Thalidomide	The serum concentration of Thalidomide can be decreased when it is combined with Dabrafenib.
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Dabrafenib.
Thiamylal	The serum concentration of Thiamylal can be decreased when it is combined with Dabrafenib.
Thiopental	The serum concentration of Thiopental can be decreased when it is combined with Dabrafenib.
Thioridazine	The serum concentration of Thioridazine can be decreased when it is combined with Dabrafenib.
Thiotepa	The serum concentration of Thiotepa can be decreased when it is combined with Dabrafenib.
Thiothixene	The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Dabrafenib.
Tiagabine	The serum concentration of Tiagabine can be decreased when it is combined with Dabrafenib.
Ticagrelor	The serum concentration of Ticagrelor can be decreased when it is combined with Dabrafenib.
Ticlopidine	The serum concentration of Ticlopidine can be decreased when it is combined with Dabrafenib.
Timolol	The serum concentration of Timolol can be decreased when it is combined with Dabrafenib.
Tinidazole	The serum concentration of Tinidazole can be decreased when it is combined with Dabrafenib.
Tiotropium	The serum concentration of Tiotropium can be decreased when it is combined with Dabrafenib.
Tipiracil	The excretion of Tipiracil can be decreased when combined with Dabrafenib.
Tipranavir	The serum concentration of Dabrafenib can be increased when it is combined with Tipranavir.
Tirzepatide	The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Dabrafenib.
Tisotumab vedotin	The serum concentration of Tisotumab vedotin can be decreased when it is combined with Dabrafenib.
Tivozanib	The metabolism of Tivozanib can be increased when combined with Dabrafenib.
Tizanidine	The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Dabrafenib.
Tocilizumab	The metabolism of Dabrafenib can be increased when combined with Tocilizumab.
Tocofersolan	The serum concentration of Tocofersolan can be decreased when it is combined with Dabrafenib.
Tocopherol	The serum concentration of Tocopherol can be decreased when it is combined with Dabrafenib.
Tofacitinib	The metabolism of Tofacitinib can be decreased when combined with Dabrafenib.
Tolazamide	The serum concentration of Tolazamide can be decreased when it is combined with Dabrafenib.
Tolbutamide	The serum concentration of Tolbutamide can be decreased when it is combined with Dabrafenib.
Tolfenamic acid	The serum concentration of Tolfenamic acid can be decreased when it is combined with Dabrafenib.

Tolterodine	The serum concentration of Tolterodine can be decreased when it is combined with Dabrafenib.
Tolvaptan	The serum concentration of Tolvaptan can be decreased when it is combined with Dabrafenib.
Topiramate	The metabolism of Dabrafenib can be increased when combined with Topiramate.
Topotecan	Dabrafenib may decrease the excretion rate of Topotecan which could result in a higher serum level.
Torasemide	The serum concentration of Torasemide can be decreased when it is combined with Dabrafenib.
Toremifene	The serum concentration of Toremifene can be decreased when it is combined with Dabrafenib.
Trabectedin	The serum concentration of Trabectedin can be decreased when it is combined with Dabrafenib.
Tramadol	The metabolism of Tramadol can be decreased when combined with Dabrafenib.
Trametinib	The risk or severity of adverse effects can be increased when Trametinib is combined with Dabrafenib.
Tranylcypromine	The metabolism of Dabrafenib can be decreased when combined with Tranylcypromine.
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Dabrafenib.
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dabrafenib.
Treprostinil	The serum concentration of Treprostinil can be increased when it is combined with Dabrafenib.
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Dabrafenib.
Triamcinolone	The serum concentration of Triamcinolone can be decreased when it is combined with Dabrafenib.
Triazolam	The serum concentration of Triazolam can be decreased when it is combined with Dabrafenib.
Triclabendazole	The serum concentration of Triclabendazole can be decreased when it is combined with Dabrafenib.
Trifluridine	The excretion of Trifluridine can be decreased when combined with Dabrafenib.
Trilaciclib	Dabrafenib may decrease the excretion rate of Trilaciclib which could result in a higher serum level.
Trimebutine	The serum concentration of Trimebutine can be decreased when it is combined with Dabrafenib.
Trimethadione	The serum concentration of Trimethadione can be decreased when it is combined with Dabrafenib.
Trimethoprim	The serum concentration of Trimethoprim can be decreased when it is combined with Dabrafenib.
Trimipramine	The serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib.
Triprolidine	The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Dabrafenib.
Triptorelin	The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dabrafenib.
Troglitazone	The serum concentration of Troglitazone can be decreased when it is combined with Dabrafenib.
Troleandomycin	The serum concentration of Dabrafenib can be increased when it is combined with Troleandomycin.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Trovafloxacin.
Tucatinib	The metabolism of Tucatinib can be decreased when combined with Dabrafenib.
Ubrogepant	The serum concentration of Ubrogepant can be increased when it is combined with Dabrafenib.
Udenafil	The serum concentration of Udenafil can be decreased when it is combined with Dabrafenib.
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Dabrafenib.
Umbralisib	The serum concentration of Dabrafenib can be increased when it is combined with Umbralisib.
Umeclidinium	The serum concentration of Dabrafenib can be increased when it is combined with Umeclidinium.
Upadacitinib	The serum concentration of Upadacitinib can be decreased when it is combined with Dabrafenib.
Valaciclovir	The excretion of Valaciclovir can be decreased when combined with Dabrafenib.
Valbenazine	The serum concentration of Valbenazine can be decreased when it is combined with Dabrafenib.
Valdecoxib	The serum concentration of Valdecoxib can be decreased when it is combined with Dabrafenib.
Valproic acid	The serum concentration of Valproic acid can be decreased when it is combined with Dabrafenib.
Valsartan	The serum concentration of Valsartan can be decreased when it is combined with Dabrafenib.
Vandetanib	The serum concentration of Vandetanib can be decreased when it is combined with Dabrafenib.
Vardenafil	The metabolism of Vardenafil can be decreased when combined with Dabrafenib.
Varenicline	The excretion of Varenicline can be decreased when combined with Dabrafenib.
Velpatasvir	The serum concentration of Velpatasvir can be decreased when it is combined with Dabrafenib.
Vemurafenib	The serum concentration of Dabrafenib can be increased when it is combined with Vemurafenib.
Venetoclax	The serum concentration of Venetoclax can be decreased when it is combined with Dabrafenib.
Venlafaxine	The serum concentration of Venlafaxine can be decreased when it is combined with Dabrafenib.
Verapamil	The serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.
Vernakalant	The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Dabrafenib.
Verteporfin	Dabrafenib may increase the photosensitizing activities of Verteporfin.
Vilanterol	The serum concentration of Vilanterol can be decreased when it is combined with Dabrafenib.
Vilazodone	The serum concentration of Vilazodone can be decreased when it is combined with Dabrafenib.
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dabrafenib.
Viloxazine	The metabolism of Dabrafenib can be decreased when combined with Viloxazine.
Vinblastine	The serum concentration of Vinblastine can be decreased when it is combined with Dabrafenib.
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Dabrafenib.
Vindesine	The serum concentration of Vindesine can be decreased when it is combined with Dabrafenib.
Vinflunine	The serum concentration of Vinflunine can be decreased when it is combined with Dabrafenib.
Vinorelbine	The serum concentration of Vinorelbine can be decreased when it is combined with Dabrafenib.
Vismodegib	The serum concentration of Vismodegib can be decreased when it is combined with Dabrafenib.
Vitamin D	The serum concentration of Vitamin D can be decreased when it is combined with Dabrafenib.
Vitamin E	The serum concentration of Vitamin E can be decreased when it is combined with Dabrafenib.
Voclosporin	The serum concentration of Dabrafenib can be increased when it is combined with Voclosporin.
Vonoprazan	Vonoprazan can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Vorapaxar	The serum concentration of Vorapaxar can be decreased when it is combined with Dabrafenib.
Voriconazole	The serum concentration of Voriconazole can be decreased when it is combined with Dabrafenib.
Vorinostat	The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Dabrafenib.
Vortioxetine	The serum concentration of Vortioxetine can be decreased when it is combined with Dabrafenib.
Voxelotor	The serum concentration of Dabrafenib can be increased when it is combined with Voxelotor.
Voxilaprevir	The serum concentration of Voxilaprevir can be decreased when it is combined with Dabrafenib.
Warfarin	The serum concentration of Warfarin can be decreased when it is combined with Dabrafenib.
Ximelagatran	The serum concentration of Ximelagatran can be decreased when it is combined with Dabrafenib.
Yohimbine	The serum concentration of Yohimbine can be decreased when it is combined with Dabrafenib.
Zafirlukast	The serum concentration of Zafirlukast can be decreased when it is combined with Dabrafenib.
Zalcitabine	The excretion of Zalcitabine can be decreased when combined with Dabrafenib.
Zaleplon	The serum concentration of Zaleplon can be decreased when it is combined with Dabrafenib.
Zanubrutinib	The serum concentration of Zanubrutinib can be decreased when it is combined with Dabrafenib.
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Dabrafenib.
Zileuton	The serum concentration of Zileuton can be decreased when it is combined with Dabrafenib.
Zimelidine	The metabolism of Dabrafenib can be decreased when combined with Zimelidine.
Ziprasidone	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Ziprasidone.
Zolmitriptan	The metabolism of Zolmitriptan can be decreased when combined with Dabrafenib.
Zolpidem	The serum concentration of Zolpidem can be decreased when it is combined with Dabrafenib.
Zonisamide	The serum concentration of Zonisamide can be decreased when it is combined with Dabrafenib.
Zopiclone	The serum concentration of Zopiclone can be decreased when it is combined with Dabrafenib.
Zotepine	The serum concentration of Zotepine can be decreased when it is combined with Dabrafenib.
Zuclopenthixol	The serum concentration of Zuclopenthixol can be decreased when it is combined with Dabrafenib.

Drug-Food Interactions

Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum levels of dabrafenib.
Avoid St. John’s Wort. This herb induces CYP3A4 metabolism, which may reduce serum levels of dabrafenib.
Do not take with or immediately after a high-fat meal. Dabrafenib’s bioavailability is reduced when taken with a high-fat meal.
Take on an empty stomach. Take dabrafenib at least one hour before or two hours after a meal.

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Pregnancy

Based on animal studies, this drug may cause fetal harm and impair fertility. This drug may decrease the efficacy of hormonal contraceptives; counsel female patients of reproductive potential to use an effective non-hormonal method of contraception during therapy and for 2 to 4 weeks after the last dose of this drug and 4 months after the last dose of trametinib when given in combination with this drug. Advise male patients of the potential risk for impaired spermatogenesis, which may be irreversible. Adequate methods of contraception should be encouraged. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Lactation

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

How should this medicine be used?

Dabrafenib comes as a capsule to take by mouth. It is usually taken twice a day on an empty stomach, 1 hour before or 2 hours after a meal. Take dabrafenib about 12 hours apart at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take dabrafenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Do not stop taking dabrafenib without talking to your doctor.

Swallow the capsules whole; do not open, break, or crush them.

Your doctor may adjust your dose or temporarily or permanently stop your treatment depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment.

Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with dabrafenib and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide.

What special precautions should I follow?

Before taking dabrafenib,

tell your doctor and pharmacist if you are allergic to dabrafenib, any other medications, or any of the ingredients in dabrafenib capsules. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac); dexamethasone; gemfibrozil (Lopid); ketoconazole; midazolam; nefazodone; rifampin (Rifadin, in Rifamate, in Rifater, Rimactane); and warfarin (Coumadin, Jantoven). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with dabrafenib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
tell your doctor if you have or have ever had diabetes; glucose-6-phosphate dehydrogenase (G6PD) deficiency (a genetic condition); bleeding problems; eye problems; heart failure or other heart problems; liver or kidney disease; or any other medical condition.
tell your doctor if you are pregnant or plan to become pregnant, or if you plan to father a child. If you are female, you will need to have a pregnancy test before you start treatment, and you should use effective birth control to prevent pregnancy during your treatment and for 2 weeks after your final dose. If you are a male and your partner can become pregnant, you should use a condom while taking this medication, and for 2 weeks after your treatment, even if you have had a vasectomy (surgery to prevent sperm from leaving your body and causing pregnancy). You should know that this medication may decrease fertility in men and women; however, you should not assume that you cannot get pregnant or that you cannot get someone else pregnant. If you or your partner becomes pregnant while taking dabrafenib, call your doctor. Dabrafenib may harm the fetus.
you should know that dabrafenib may decrease the effectiveness of hormonal contraceptives (birth control pills, patches, rings, implants, and injections). You should use another method of birth control to prevent pregnancy in yourself or your partner during your treatment with dabrafenib and for 2 weeks after your final dose. Talk to your doctor about birth control methods that will work for you.
tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while taking dabrafenib and for 2 weeks after your final dose.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking dabrafenib.

References

https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf
https://pubchem.ncbi.nlm.nih.gov/compound/Dabrafenib
https://pubchem.ncbi.nlm.nih.gov/compound/Dabrafenib-mesylate
https://en.wikipedia.org/wiki/Dabrafenib
https://medlineplus.gov/druginfo/meds/a613038.html
https://go.drugbank.com/drugs/DB08912
https://www.drugs.com/mtm/dabrafenib.htm
https://www.webmd.com/drugs/2/drug-164393/dabrafenib-oral/details/list-contraindications
https://www.mayoclinic.org/drugs-supplements/dabrafenib-oral-route/proper-use/drg-20061178
ChemIDplus
LICENSE
https://www.nlm.nih.gov/copyright.html
Dabrafenib [USAN:INN]
https://chem.nlm.nih.gov/chemidplus/sid/1195765457
ChemIDplus Chemical Information Classification
https://chem.nlm.nih.gov/chemidplus/
DrugBank
https://www.drugbank.ca/legal/terms_of_use
Dabrafenib
https://www.drugbank.ca/drugs/DB08912
EPA DSSTox
LICENSE
https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
Dabrafenib
https://comptox.epa.gov/dashboard/DTXSID20152499
CompTox Chemicals Dashboard Chemical Lists
https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)
https://echa.europa.eu/web/guest/legal-notice
N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
https://echa.europa.eu/substance-information/-/substanceinfo/100.215.965
N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/221221
FDA Global Substance Registration System (GSRS)
https://www.fda.gov/about-fda/about-website/website-policies#linking
DABRAFENIB
https://gsrs.ncats.nih.gov/ginas/app/beta/substances/QGP4HA4G1B
ChEBI
Dabrafenib
http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75045
ChEBI Ontology
http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
FDA Pharm Classes
https://www.fda.gov/about-fda/about-website/website-policies#linking
DABRAFENIB
https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
FDA Pharmacological Classification
https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
LiverTox
LICENSE
https://www.nlm.nih.gov/copyright.html
Dabrafenib
https://www.ncbi.nlm.nih.gov/books/n/livertox/Dabrafenib/
NCI Thesaurus (NCIt)
https://www.cancer.gov/policies/copyright-reuse
https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82386
NCI Thesaurus Tree
https://ncit.nci.nih.gov
ClinicalTrials.gov
https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
https://clinicaltrials.gov/
Comparative Toxicogenomics Database (CTD)
http://ctdbase.org/about/legal.jsp
https://ctdbase.org/detail.go?type=chem&acc=C561627
Drug Gene Interaction database (DGIdb)
http://www.dgidb.org/downloads
https://www.dgidb.org/drugs/DABRAFENIB
IUPHAR/BPS Guide to PHARMACOLOGY
https://www.guidetopharmacology.org/about.jsp#license
https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6494
Guide to Pharmacology Target Classification
https://www.guidetopharmacology.org/targets.jsp
Therapeutic Target Database (TTD)
Dabrafenib
http://idrblab.net/ttd/data/drug/details/D05ROI
Nature Chemical Biology
https://pubchem.ncbi.nlm.nih.gov/substance/405544700
European Medicines Agency (EMA)
https://www.ema.europa.eu/en/about-us/legal-notice
Tafinlar (EMEA/H/C/002604)
https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar
Drugs and Lactation Database (LactMed)
LICENSE
https://www.nlm.nih.gov/copyright.html
Dabrafenib
https://www.ncbi.nlm.nih.gov/books/NBK500855/
EU Clinical Trials Register
https://www.clinicaltrialsregister.eu/
FDA Orange Book
https://www.fda.gov/about-fda/about-website/website-policies#linking
https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
NORMAN Suspect List Exchange
LICENSE
Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
https://creativecommons.org/licenses/by/4.0/
NORMAN Suspect List Exchange Classification
https://www.norman-network.com/nds/SLE/
WHO Anatomical Therapeutic Chemical (ATC) Classification
https://www.whocc.no/copyright_disclaimer/
https://www.whocc.no/atc/
ATC Code
https://www.whocc.no/atc_ddd_index/
FDA Medication Guides
https://www.fda.gov/about-fda/about-website/website-policies#linking
Tafinlar
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page
National Drug Code (NDC) Directory
https://www.fda.gov/about-fda/about-website/website-policies#linking
DABRAFENIB
https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
Human Metabolome Database (HMDB)
http://www.hmdb.ca/citing
Dabrafenib
http://www.hmdb.ca/metabolites/HMDB0250818
NCI Cancer Drugs
LICENSE
https://www.cancer.gov/policies/copyright-reuse
Dabrafenib Mesylate
https://www.cancer.gov/about-cancer/treatment/drugs/dabrafenib
NIPH Clinical Trials Search of Japan
https://rctportal.niph.go.jp/en/
NLM RxNorm Terminology
https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
dabrafenib
https://rxnav.nlm.nih.gov/id/rxnorm/1424911
Protein Data Bank in Europe (PDBe)
http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P06
PubChem
https://pubchem.ncbi.nlm.nih.gov
PFAS and Fluorinated Compounds in PubChem
https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
RCSB Protein Data Bank (RCSB PDB)
https://www.rcsb.org/pages/policies
https://www.rcsb.org/
Springer Nature
https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=35061485-726864646
Thieme Chemistry
https://creativecommons.org/licenses/by-nc-nd/4.0/
https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=35061485-726864646
Wikidata
LICENSE
CCZero
https://creativecommons.org/publicdomain/zero/1.0/
Dabrafenib
https://www.wikidata.org/wiki/Q3011604
Medical Subject Headings (MeSH)
https://www.nlm.nih.gov/copyright.html
dabrafenib
https://www.ncbi.nlm.nih.gov/mesh/67561627
MeSH Tree
http://www.nlm.nih.gov/mesh/meshhome.html
Antineoplastic Agents
https://www.ncbi.nlm.nih.gov/mesh/68000970
Protein Kinase Inhibitors
https://www.ncbi.nlm.nih.gov/mesh/68047428
KEGG
https://www.kegg.jp/kegg/legal.html
Anatomical Therapeutic Chemical (ATC) classification
http://www.genome.jp/kegg-bin/get_htext?br08303.keg
Target-based classification of drugs
http://www.genome.jp/kegg-bin/get_htext?br08310.keg
Drug Groups
http://www.genome.jp/kegg-bin/get_htext?br08330.keg
UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
GHS Classification Tree
http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
ChEMBL
http://www.ebi.ac.uk/Information/termsofuse.html
ChEMBL Protein Target Tree
https://www.ebi.ac.uk/chembl/g/#browse/targets
PATENTSCOPE (WIPO)
SID 391944689
https://pubchem.ncbi.nlm.nih.gov/substance/391944689
NCBI
https://www.ncbi.nlm.nih.gov/projects/linkout